

January 26, 2021

Information Quality Guidelines Staff
Mail Code 2811R
Environmental Protection Agency
1200 Pennsylvania Avenue, N.W.
Washington, D.C. 20460

Re: Request for Correction
Risk Evaluation for Carbon Tetrachloride; EPA-HQ-OPPT-2019-0499

Dear Sir or Madam:

This request for the correction of information (“Request for Correction”) is submitted under the Information Quality Act (“IQA”)¹ and the implementing guidelines issued, respectively, by the Office of Management and Budget (“OMB”)² and the Environmental Protection Agency (“EPA”),³ on behalf of the Halogenated Solvents Industry Alliance, Inc. (“HSIA”). HSIA represents producers and users of carbon tetrachloride (“CTC”) and other chlorinated solvents. As discussed below, HSIA seeks the correction of information disseminated in an EPA document “Risk Evaluation for Carbon Tetrachloride (Methane, Tetrachloro-); CAS RN: 56-23-5” issued pursuant to § 6 of the Toxic Substances Control Act (TSCA).⁴

This Request is organized as follows:

- I. Summary of Request for Correction
- II. EPA’s IQA Guidelines

¹ Section 515(a) of the Treasury and General Government Appropriations Act for Fiscal Year 2001, P.L. 106-554; 44 U.S.C. § 3516 (notes).

² 67 Fed. Reg. 8452 (Feb. 22, 2002) (“OMB Guidelines”).

³ EPA, Guidelines for Ensuring and Maximizing the Quality, Objectivity, Utility, and Integrity, of Information Disseminated by the Environmental Protection Agency, EPA/260R-02-008 (October 2002) (“EPA Guidelines”).

⁴ EPA-740-R1-8014 (October 2020) (hereafter “Risk Evaluation”). HSIA notes that while TSCA § 21 provides for citizens’ petitions, these are limited to proceedings for the issuance, amendment, or repeal *of a rule*. Nevertheless, we encourage EPA to treat this request as part of the process of “integrat[ing] and assess[ing] available information on hazards and exposures for the conditions of use of [CTC], including information that is relevant to specific risks of injury to health or the environment and information on potentially exposed or susceptible subpopulations” pursuant to TSCA § 6(b)(4)(F) (i) and “describ[ing] the weight of the scientific evidence for the identified hazard and exposure” pursuant to TSCA § 6(b)(4)(F)(v), and to add this Request to the captioned TSCA docket.

- III. Dermal Exposure Assessment in the CTC Risk Evaluation
- IV. Hazard Assessment in the CTC Risk Evaluation
- V. Conclusion

I. Summary of Request for Correction

EPA selected CTC as one of the initial ten substances to be evaluated under TSCA as amended in 2016. CTC is an industrial chemical that was once in widespread use but is now tightly regulated under the Montreal Protocol on Substances That Deplete the Ozone Layer and Title VI of the Clean Air Act (CAA). Because of its ozone depletion potential, this regulatory program phased out the manufacture and import of CTC over 20 years ago, subject to limited exceptions such as use as a process agent or feedstock, where by definition it is used and entirely consumed, except for trace quantities.⁵ Furthermore, facilities that manufacture CTC and use it as an intermediate are covered by National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Synthetic Organic Chemical Manufacturing Industry (SOCMI),⁶ which require closed systems where exposure is tightly controlled. And such facilities must meet workplace limits enforced by the Occupational Safety & Health Administration (OSHA).

HSIA requests correction of the CTC Risk Evaluation at this step of the TSCA process to correct two key deficiencies:

- The CTC Risk Evaluation fails to incorporate longstanding workplace practices recognized and required by EPA in the NESHAP. It instead relies on unrealistic assumptions about dermal exposure in the manufacturing sector, resulting in an amount of CTC absorbed by workers from skin contact that is thousands of times higher than from real world exposures.
- The CTC Risk Evaluation uses a linear non-threshold model coupled with an assumption that the principal study relied upon did not produce a no-observed-adverse-effect level (NOAEL), both in disregard of advice provided by outside peer reviewers, again resulting in estimates of risk thousands of times higher than reality.

These errors not only result in inaccurate findings but provide erroneous starting points for risk management. The implications for US manufacturing of EPA's findings based on incorrect information are enormous. For example, the Kigali Amendment to the Montreal Protocol, which mandates a global phase down of HFCs, is predicated on the widespread availability of low Global Warming Potential (GWP) HFO alternatives such as HFO-1234yf, -1234ze, and -1233zd. Carbon tetrachloride is the critical feedstock for US production of these low-GWP alternatives.

Accordingly, HSIA urges EPA to give full and prompt consideration to this Request for Correction.

⁵ Title VI of the Clean Air Act (implementing the Montreal Protocol) restricts the production and consumption of carbon tetrachloride. See also the implementing regulations at 40 C.F.R. Part 82, Subpart A.

⁶ 40 C.F.R. 63 Subparts F, G, H, I (hereafter "the NESHAP").

II. EPA's IQA Guidelines

The CTC Risk Evaluation was among the first issued by EPA under TSCA as amended in 2016. This underscores the importance of the Risk Evaluation meeting EPA's key IQA Performance Goals of objectivity, utility, and integrity.⁷ Because these TSCA evaluations will have such an impact on the manufacturing sector, it is imperative that they utilize accurate data.

A. Influential Scientific Information

As does OMB, EPA considers the “objectivity” inquiry for IQA purposes to be “whether the disseminated information is being presented in an accurate, clear, complete, and unbiased manner, and as a matter of substance, is accurate, reliable, and unbiased.” To ensure the objectivity of “influential scientific risk assessment information,” EPA adapted the quality principles from the Safe Drinking Water Act Amendments of 1996, as follows:

“(A) The substance of the information is accurate, reliable and unbiased. This involves the use of:

(i) the best available science and supporting studies conducted in accordance with sound and objective scientific practices, including, when available, peer reviewed science and supporting studies; and

(ii) data collected by accepted methods or best available methods (if the reliability of the method and the nature of the decision justifies the use of the data).

“(B) The presentation of information on human health, safety, or environmental risks, consistent with the purpose of the information, is comprehensive, informative, and understandable.”⁸

In calling for the use of “best available science,” the EPA Guidelines expressly recognize that “scientific knowledge about risk is rapidly changing and ... risk information may need to be updated over time.”⁹ Moreover, EPA recognizes that the “*influential* scientific, financial, or statistical information” it disseminates “should meet a higher standard of quality.”¹⁰ Under the EPA Guidelines, information is considered influential if “the Agency can reasonably determine that dissemination of the information will have or does have a clear and substantial impact (*i.e.*,

⁷ EPA Guidelines at 9. EPA's IQA Guidelines “contain EPA's policy and procedural guidance for ensuring and maximizing the quality of information [it] disseminate[s]” as well as specifically describing “new mechanisms to enable affected persons to seek and obtain corrections from EPA regarding disseminated information that they believe does not comply with EPA or OMB guidelines.” *Id.* at 3.

⁸ *Id.* at 22.

⁹ *Id.* at 23.

¹⁰ *Id.* at 19 (emphasis added).

potential change or effect) on important public policies or private sector decisions.”¹¹ More specifically, information is “influential” if it is disseminated in support of top Agency actions (*i.e.*, rules...).”¹²

The EPA Guidelines further recognize that an “influential” risk assessment should be revised where, as here, the assessment will have a “clear and substantial impact” on private sector decisions.¹³ The “clear and substantial impact” standard is met here, as otherwise the erroneous Risk Evaluation will result in rules requiring manufacturers to make decisions and expend significant resources to address non-existent risks.

B. Other IQA Performance Goals

EPA should also correct the errors identified to meet the IQA's second performance goal, one of integrating information quality "into each step of EPA's development of information, including creation, collection, maintenance and dissemination." In addition, the third performance goal in EPA's IQA Guidelines states that the means for correction should be "appropriate to the nature and timeliness of the disseminated information." As discussed above, addressing errors incorporated in the CTC Risk Evaluation is appropriate and necessary before EPA begins the risk management rule-making process.

C. Substantive TSCA Requirements for Scientific Information

TSCA, as amended in 2016, is entirely consistent with EPA's IQA Guidelines. TSCA §§ 6 and 26 expressly require that risk evaluations for existing chemicals be based on “best available science” and the “weight of the scientific evidence.” As described in more detail below, the TSCA Science Advisory Committee on Chemicals (SACC) rejected EPA’s concern that low-level exposures to carbon tetrachloride may somehow cause tumors through a genotoxic mode of action. The SACC expressly concluded that EPA’s “underlying justification for using the “default” approach of applying a linearized model to the tumor mouse bioassay data in order to predict low-dose cancer-risk” is *not supported by the weight of the evidence*.¹⁴

III. **Dermal Exposure Assessment in the CTC Risk Evaluation**

The Risk Evaluation concludes that CTC presents unreasonable risks to workers under 13 of 15 conditions of use (COUs) with or without Personal Protective Equipment (PPE), as well as to occupational non-users (ONUs) without PPE.¹⁵ For dermal exposure, although unsupported by

¹¹ *Id.*

¹² *Id.* at 20.

¹³ *Id.*

¹⁴ <https://www.regulations.gov/document?D=EPA-HQ-OPPT-2019-0499-0046> at 39.

¹⁵ To be clear, while the focus of this section is dermal exposure, the flawed approach to the cancer mode of action criticized by the SACC underlies the unreasonable risk determinations for other COUs based on inhalation exposure as well. The problems with the hazard assessment are addressed in the following section.

actual data, EPA finds unreasonable cancer risks to workers under all 13 of these COUs even with the most protective glove use (Protection Factor of 20). In the absence of dermal exposure data for CTC, EPA relied on models to estimate the amount of CTC that is retained by workers from dermal contact. These “worst-case scenarios” assume unrealistic dermal exposure durations and fail to recognize basic industrial hygiene (IH) practices, as well as engineering controls required by the NESHAP. Thus, they are clearly inapplicable to facilities that manufacture CTC or use CTC as a process reactant or intermediate.

The manufacture of CTC and its use as in the production of other chemicals (*i.e.*, perchloroethylene, HFOs) are COUs that occur in closed system process units where potential dermal contact is limited to short-term tasks in the operation of unit activities. The typical tasks that could potentially involve contact with liquid phase CTC are handling of transfer lines for vessel charging/uncharging and collecting samples from process points for laboratory analysis. In general, these tasks would involve limited direct contact with liquid, and the duration of any potential contact with the liquid is very short (*i.e.*, minutes).

EPA estimated dermal exposure to CTC for workers using Kasting and Miller (2006)¹⁶ with the following assumptions: (1) one dermal contact with undiluted CTC which coats fully one or both hands per work shift; (2) workers do not wash their hands at any point during the 8-hour work shift if gloves are not worn; and (3) a worker wears the same pair of gloves for the entire 8-hour work shift without stopping to wash their hands and/or change their gloves.¹⁷ Incredibly, EPA provides no documentation or justification for these assumptions other than the intent to establish a theoretical “worst-case scenario.” As a result of these assumptions, EPA has substantially overestimated worker exposure to CTC from dermal contact in facilities that manufacture and use CTC as a reactant or intermediate.

According to EPA, risk evaluations under TSCA § 6(b) are not screening level risk assessments, but are intended to “use scientific information, technical procedures, measures, protocols, methodologies and models consistent with the best available science.” Therefore, EPA should consider in its dermal exposure models assumptions that are relevant and appropriate to actual workplace practices for the COUs being evaluated. Unfortunately, the CTC Risk Evaluation failed to acknowledge basic IH practices.

For CTC facilities with closed systems, any potential dermal exposures are for short durations and, combined with the industry standards for good IH practices at these facilities which require removal and disposal of potentially contaminated gloves and hand washing after each task completion, do not justify an 8-hour period for absorption of CTC through skin. Moreover, CTC will evaporate from the skin and gloves between exposure periods. A more realistic approach to estimating the dermal dose of CTC in workers in closed system facilities (manufacturing and

¹⁶ Kasting, BG, Miller, MA, Kinetics of finite dose absorption through skin 2: Volatile compounds. J. Pharm. Sci. 95: 268-280 (2006).

¹⁷ Risk Evaluation, Supplemental Information on Releases and Occupational Exposure Assessment.

process reactant/intermediate use) can be obtained using the IH Skin Perm model.¹⁸ This tool is commonly used by practitioners of IH and exposure assessment to produce reliable estimates of dermal exposure. And, as noted in the Risk Evaluation, “this model takes into account losses to evaporation and estimates the mass that is absorbed.” In addition, IH SkinPerm can be used to evaluate the impacts of differing patterns of exposure on fractional and total dose of absorption, i.e., it allows for the incorporation of realistic exposure patterns.

Using the IH Skin Perm model and a more realistic, albeit still conservative, period for exposure and absorption after tasks, allowing for handwashing, and assuming skin exposure had occurred for up to 1 hour before removal, we can estimate the dermal absorbed dose for COUs involving manufacturing of CTC and its use as a reactant or intermediate in the production of other chemicals. For ungloved hands, the amount of CTC absorbed from exposure to two full hands is 2.78 mg/day. In comparison, EPA estimated the amount of CTC absorbed to be 90 mg/day for two full hands (high-end estimate). Thus, the impact of using a more realistic approach to estimating the high-end dermal CTC dose over one hour results in an approximately 32-fold reduction in the dermal dose.

This overestimate of dermal dose is expected also to hold true in the Risk Evaluation for gloved hands, the only difference being that there is reduced dermal uptake from glove use, and this is accounted for by a workplace protection factor. It is also important to note that these models assume that a worker is exposed to neat or undiluted chemical. Such exposure is highly unlikely in facilities that manufacture CTC or use it as a reactant or intermediate in closed systems. As a result of using unrealistic worst-case assumptions in its dermal exposure assessment, EPA has substantially overestimated worker exposure to CTC from dermal contact by at least several orders of magnitude. *Thus, if the revised scenarios were applied in the risk characterization, there would be no unreasonable risk to workers from dermal exposure!*

Recognition of standard work practices and reliance on reasonable and realistic exposure data are critical to meet the “objectivity” criterion of the IQA and the statutory requirements of TSCA. EPA’s reliance on hypothetical assumptions for modeling of the amount of CTC that is absorbed by workers from dermal contact cannot be justified. Assumptions used for estimating worker exposures should be as relevant as possible for the COUs being evaluated. EPA’s use of unrealistic dermal exposure assumptions has led to erroneous conclusions regarding the health risks to workers using CTC in closed systems. Because the Risk Evaluation is intended to determine whether CTC presents an unreasonable risk of injury to workers under TSCA § 6(b), which requires rulemaking to mitigate risks found to be unreasonable, it is imperative that it be revised to reflect the “best available science.”

¹⁸ IH SkinPerm is a peer-reviewed exposure assessment tool published by the American Industrial Hygiene Association (AIHA) Exposure Assessment Strategies Committee. Oddly this model was not used by EPA to estimate the dermal dose for workers in the Risk Evaluation, although Table 2-23 includes output data from it under various dermal exposure scenarios.

IV. Hazard Assessment in the CTC Risk Evaluation

The CTC Risk Evaluation uses a linear non-threshold model coupled with an assumption that the principal study relied upon did not produce a no-observed-adverse-effect level (NOAEL), both in disregard of advice provided by outside peer reviewers. As a result, as described in more detail below, the estimates are overly conservative by at least a thousand-fold.

The Risk Evaluation relies on Nagano *et al.*, (2007) to derive both the cancer inhalation unit risk (IUR) and the dermal slope factor. The IUR estimates based on Nagano *et al.* (2007) were calculated by the EPA IRIS Program in 2010. The IUR selected for carbon tetrachloride via the inhalation pathway was $6 \times 10^{-6} (\mu\text{g}/\text{m}^3)^{-1}$, which was associated with pheochromocytomas in the male mouse. The data set on pheochromocytomas in the male mouse was also judged by the EPA IRIS Program to yield the highest estimate of risk.¹⁹

As in the case of the dermal exposure assessment, this approach does not meet the “objectivity” criterion of the IQA (requiring “the best available science and supporting studies conducted in accordance with sound and objective scientific practices, including, when available, peer reviewed science and supporting studies”). Moreover, it patently departs from EPA’s recognition, in calling for the use of “best available science,” that “scientific knowledge about risk is rapidly changing and ... risk information may need to be updated over time.”²⁰

In the IRIS CTC assessment, EPA concluded that there is insufficient information on the mode of action (MOA) of CTC for mouse liver tumors at low doses and the mouse pheochromocytomas to support a non-linear dose-response approach for assessing cancer risk. A majority (four out of six) of the external peer reviewers, however, recommended that potential CTC cancer risk should be based on a non-linear threshold method. To quote directly from the IRIS response to reviewer comments: “Two reviewers considered it appropriate to present a linear low-dose extrapolation approach as an alternative approach, but that based on available evidence, the nonlinear method seems more appropriate.” A fifth reviewer stated that use of a linear dose-response model is “difficult to defend and is not a preferable approach” [and a] “sixth reviewer did not agree that a linear assessment is justified for carbon tetrachloride.” Even one of the two reviewers who believed that a low-dose linear approach was the “most clear, prudent and scientifically defensible approach” noted that use of a nonlinear approach is “reasonable to consider,” although noting that such an approach might use an additional, possibly 10-fold, uncertainty factor to assure protection of both cancer and non-cancer endpoints.²¹

The final Risk Evaluation included a nonlinear dose-response assessment, but departed from the advice of the TSCA Science Advisory Committee on Chemicals (SACC), which was quite clear that a threshold MOA should be used for CTC:

¹⁹ Risk Evaluation at 167.

²⁰ EPA Guidelines at 23.

²¹ https://cfpub.epa.gov/ncea/iris/iris_documents/documents/toxreviews/0020tr.pdf at A-25.

“The Committee concluded that the weight of a considerable body of scientific evidence indicates that the relationship between carbon tetrachloride dose/exposure and its genotoxic response is nonlinear with a steep dose-response. Less is known about mechanisms underlying adrenal gland tumors in rodents or apparent glioblastomas [sic] in workers. Most of the Committee members recommended that the EPA consider adoption and implementation of a threshold MOA when estimating cancer risks.”²²

Indeed, the Committee highlighted the following recommendation:

“Recommendation 55: Consider adoption of a threshold-type MOA in estimating the carcinogenic risks of carbon tetrachloride.

“Mechanisms underlying the carcinogenicity of carbon tetrachloride in the rodent liver have been studied extensively. Using a WOE approach, it is likely that the relationship between carbon tetrachloride dose per exposure and its genotoxic response is nonlinear with a steep dose response. This conclusion is primarily based upon the MOA identified from numerous genotoxicity investigations, as well as several important factors that support/indicate a nonlinear dose-response. These include recognition that:

1. The primary site of carbon tetrachloride bioactivation and adverse effects is the smooth endoplasmic reticulum, a site removed from the nucleus and DNA;
2. The moieties which are formed are highly reactive and unlikely to travel far in the aqueous cytoplasm from their site of formation;
3. The observed genotoxic effects appear to result from indirect mechanisms related to oxidative and lipid peroxidation-mediated DNA damage, or damage occurring due to necrosis and apoptosis;
4. Carbon tetrachloride metabolite-induced lipid peroxidation is an exponential chain reaction, such that a single initiation event can lead to formation of many reactive species. Thus, the extent of damage can have a distinct nonlinear component;
5. High levels of hepatoprotective agents and antioxidants are present in hepatocytes;
6. A close relationship is manifest between cytotoxicity and genotoxicity;
7. Oxidative and lipoperoxidation-related DNA damage occurs spontaneously in untreated cells, and has been shown to be efficiently repaired; and

²² <https://www.regulations.gov/document?D=EPA-HQ-OPPT-2019-0499-0046> at 50.

8. Apoptosis and recognition and destruction of transformed cells by the immune system are additional protective mechanisms that argue against use of a linear dose-response model.”²³

The Committee concluded:

“[A]lthough the Evaluation claims to have ‘Evaluated the weight of the scientific evidence based on the available human health hazard data for carbon tetrachloride,’ the Committee noted that convincing support for this claim is lacking. In particular, the Evaluation refers repeatedly to a concern that low-level exposures to carbon tetrachloride may somehow act through genotoxic mechanisms (evidence for this notwithstanding); indeed, this concern is its underlying justification for using the “default” approach of applying a linearized model to the tumor mouse bioassay data in order to predict low-dose cancer-risk. *But the weight of evidence clearly indicates that any genotoxicity caused by carbon tetrachloride can occur only at exceedingly high levels of exposure, and is caused not by carbon tetrachloride directly, but only indirectly after high levels of lipid peroxide by-products (such as reactive aldehydes) have accumulated intracellularly. . . . No support is provided for EPA’s designation of an ‘alternate MOA’ that combines cytotoxic mechanisms at relatively high CCl₄ doses with ‘alternate, non-cytotoxic mechanisms’ at lower doses.*”²⁴

Although the Risk Evaluation includes cancer risk estimates derived using a non-linear approach, the calculations are based on a point of departure (POD) of 5 ppm. EPA interpreted the increase in liver tumors in the female mice at this concentration as a treatment-related lowest-observed-adverse-effect level (LOAEL). As noted by the SACC, however, the scientific justification for using a nonlinear approach here is that the MOA for CTC-induced liver tumors involves cytotoxicity and proliferation from the highly reactive radical metabolites of CTC. Thus, liver toxicity is a precursor key event to CTC-induced liver tumors. In the Nagano study there was no indication of liver toxicity in the livers of female mice exposed to 5 ppm. Accordingly, EPA’s use of 5 ppm as a LOAEL for its derivation of cancer risk is incompatible with the underlying assumption regarding the MOA. Given the preponderance of science evidence for the cytotoxic-proliferative MOA for CTC carcinogenicity, the weight-of-the-evidence suggests that the increase in female mouse liver tumors at 5 ppm occurred by chance and that this exposure concentration is instead a NOAEL.

Indeed, the SACC stated:

“No support is provided for the EPA’s designation of an “alternate MOA” that combines cytotoxic mechanisms at relatively high carbon tetrachloride doses with “alternate, non-cytotoxic mechanisms” at lower doses. What is meant by an

²³ *Id.* at 51-52.

²⁴ *Id.* at 39 (references omitted and emphasis added).

“alternate non-cytotoxic mechanism” (Evaluation Page 124, line 4005)? This appears to be speculation that something must be occurring to produce an increased incidence in liver adenomas in the female mice dosed at five ppm. Consideration should be given to the possibility that this was a chance occurrence in a single study. The historical incidence of this benign tumor in control Crj:BDF1 mice is as high as 10%. Had three of 50 control females exhibited liver adenoma in this particular experiment, the difference between them and the five ppm dose group would not have been statistically significant. There was no increase in liver carcinoma incidence in the females dosed at five ppm and no significant increase over controls in combined benign and malignant liver tumors. It should also be noted there was no increase in hepatocellular adenoma or carcinoma in the male mice dosed at five ppm. Male mice metabolically activate more carbon tetrachloride and experience a higher incidence of liver cancer than do females.”

The peer review excerpts quoted above make clear that the Committee disagreed with EPA and supported a non-linear assessment based on a 5 ppm NOAEL. Further, the Committee made clear its view that EPA was not using a weight-of-the-evidence approach. This is highly significant given the admonition in TSCA § 26(i) that “[t]he Administrator shall make decisions under sections 4, 5, and 6 based on the weight of the scientific evidence.” It is unusual for peer reviewers to place so much emphasis on a recommendation, and even more unusual for EPA to disregard such a recommendation when it echoes earlier advice received from different external peer reviewers on the same subject.

Significantly, there is a recent and readily available Substance Evaluation Conclusion for CTC prepared by France as a part of the substance evaluation process under the REACH Regulation (EC) No 1907/2006 (enclosed). Unlike the EPA Evaluation, but consistent with the outside peer reviewers here, this weight-of-the-evidence review combines a nonlinear, threshold mode of action with a nongenotoxic mode of action:

“Taking into account the results of genotoxicity data, CCl₄ [CTC] is not considered as a direct genotoxic agent but acts as a carcinogen by a threshold mode of action. Cytotoxicity and regeneration seem therefore to be a main factor in the apparition [sic] of (pre-)neoplastic lesions. In conclusion, CCl₄ is considered to act as a carcinogen by a threshold mode of action.”

Based on this conclusion, the French evaluation derives a NOAEL of 5 ppm (32 mg/m³) for hepatoadenomas and carcinomas in both species after chronic exposure to CTC via the inhalation route. This is in line with the workplace limit enforced by OSHA (10 ppm) and that recommended by the American Conference of Governmental Hygienists (5 ppm), and some thousand times higher than the level deemed acceptable by EPA. HSIA strongly recommends that EPA recognize the 5 ppm NOAEL and use it, along with a nonlinear MOA, as the basis for a revised cancer risk assessment.

V. Conclusion

Prompt action on this Request for Correction is necessary in order for the EPA Risk Evaluation to comply with the IQA and TSCA, and to avoid EPA basing risk management regulations for CTC on erroneous scientific data and interpretation.

Respectively submitted,

A handwritten signature in black ink, appearing to read "Christopher Bevan". The signature is fluid and cursive, with the first name "Christopher" written in a larger, more prominent script than the last name "Bevan".

Christopher Bevan, PhD, MPH, DABT
Director, Scientific Programs

Enclosure

cc: Deputy Assistant Administrator Michal Ilana Freedhoff
Mr. Mark Hartman
Mr. Joel Wolf
Mr. Erik Winchester
Mr. Douglas Parsons
W. Caffey Norman, Esq.



SUBSTANCE EVALUATION CONCLUSION

as required by REACH Article 48

and

EVALUATION REPORT

for

Carbon tetrachloride

EC No 200-262-8

CAS No 56-23-5

Evaluating Member State(s): France

Dated: December 2019

Evaluating Member State Competent Authority

France

Anses

14 rue Pierre et Marie Curie

94701 Maisons-Alfort Cedex

Year of evaluation in CoRAP: 2012

Before concluding the substance evaluation a Decision to request further information was issued on: 26.02.2014. This Decision was annulled by the Board of Appeal the 23rd of September 2015 (case A-005-2014).

Further information on registered substances here:

<http://echa.europa.eu/web/guest/information-on-chemicals/registered-substances>

DISCLAIMER

This document has been prepared by the evaluating Member State as a part of the substance evaluation process under the REACH Regulation (EC) No 1907/2006. The information and views set out in this document are those of the author and do not necessarily reflect the position or opinion of the European Chemicals Agency or other Member States. The Agency does not guarantee the accuracy of the information included in the document. Neither the Agency nor the evaluating Member State nor any person acting on either of their behalves may be held liable for the use which may be made of the information contained therein. Statements made or information contained in the document are without prejudice to any further regulatory work that the Agency or Member States may initiate at a later stage.

Foreword

Substance evaluation is an evaluation process under REACH Regulation (EC) No. 1907/2006. Under this process the Member States perform the evaluation and ECHA secretariat coordinates the work. The Community rolling action plan (CoRAP) of substances subject to evaluation, is updated and published annually on the ECHA web site¹.

Substance evaluation is a concern driven process, which aims to clarify whether a substance constitutes a risk to human health or the environment. Member States evaluate assigned substances in the CoRAP with the objective to clarify the potential concern and, if necessary, to request further information from the registrant(s) concerning the substance. If the evaluating Member State concludes that no further information needs to be requested, the substance evaluation is completed. If additional information is required, this is sought by the evaluating Member State. The evaluating Member State then draws conclusions on how to use the existing and obtained information for the safe use of the substance.

This Conclusion document, as required by Article 48 of the REACH Regulation, provides the final outcome of the Substance Evaluation carried out by the evaluating Member State. The document consists of two parts i.e. A) the conclusion and B) the evaluation report. In the conclusion part A, the evaluating Member State considers how the information on the substance can be used for the purposes of regulatory risk management such as identification of substances of very high concern (SVHC), restriction and/or classification and labelling. In the evaluation report part B the document provides explanation how the evaluating Member State assessed and drew the conclusions from the information available.

With this Conclusion document the substance evaluation process is finished and the Commission, the Registrant(s) of the substance and the Competent Authorities of the other Member States are informed of the considerations of the evaluating Member State. In case the evaluating Member State proposes further regulatory risk management measures, this document shall not be considered initiating those other measures or processes. Further analyses may need to be performed which may change the proposed regulatory measures in this document. Since this document only reflects the views of the evaluating Member State, it does not preclude other Member States or the European Commission from initiating regulatory risk management measures which they deem appropriate.

¹ <http://echa.europa.eu/regulations/reach/evaluation/substance-evaluation/community-rolling-action-plan>

Contents

| | |
|---|-----------|
| Part A. Conclusion | 7 |
| 1. CONCERN(S) SUBJECT TO EVALUATION | 7 |
| 2. OVERVIEW OF OTHER PROCESSES / EU LEGISLATION | 7 |
| 3. CONCLUSION OF SUBSTANCE EVALUATION | 7 |
| 4. FOLLOW-UP AT EU LEVEL..... | 8 |
| 4.1. Need for follow-up regulatory action at EU level | 8 |
| 4.1.1. Harmonised Classification and Labelling | 8 |
| 4.1.2. Identification as a substance of very high concern, SVHC (first step towards authorisation) .. | 9 |
| 4.1.3. Restriction | 9 |
| 4.1.4. Other EU-wide regulatory risk management measures | 9 |
| 5. CURRENTLY NO FOLLOW-UP FORESEEN AT EU LEVEL..... | 9 |
| 6. TENTATIVE PLAN FOR FOLLOW-UP ACTIONS (IF NECESSARY) | 9 |
| Part B. Substance evaluation | 11 |
| 7. EVALUATION REPORT..... | 11 |
| 7.1. Overview of the substance evaluation performed..... | 11 |
| 7.2. Procedure..... | 12 |
| 7.3. Identity of the substance | 13 |
| 7.4. Physico-chemical properties | 14 |
| 7.5. Manufacture and uses..... | 16 |
| 7.5.1. Quantities..... | 16 |
| 7.5.2. Overview of uses..... | 17 |
| 7.6. Classification and Labelling..... | 17 |
| 7.6.1. Harmonised Classification (Annex VI of CLP) | 17 |
| 7.6.2. Self-classification | 18 |
| 7.7. Environmental fate properties..... | 18 |
| 7.7.1. Degradation..... | 18 |
| 7.7.2. Environmental distribution | 19 |
| 7.7.3. Bioaccumulation | 19 |
| 7.8. Environmental hazard assessment | 19 |
| 7.8.1. Aquatic compartment (including sediment) | 19 |
| 7.8.2. Terrestrial compartment..... | 20 |
| 7.8.3. Microbiological activity in sewage treatment systems | 21 |
| 7.8.4. PNEC derivation and other hazard conclusions..... | 21 |
| 7.9. Human Health hazard assessment | 22 |
| 7.9.1. Toxicokinetics | 22 |
| 7.9.2. Acute toxicity and Corrosion/Irritation | 22 |
| 7.9.3. Sensitisation | 23 |
| 7.9.4. Repeated dose toxicity..... | 23 |
| 7.9.5. Mutagenicity | 27 |
| 7.9.6. Carcinogenicity | 28 |

| | |
|--|----|
| 7.9.7. Toxicity to reproduction (effects on fertility and developmental toxicity)..... | 31 |
| 7.9.8. Hazard assessment of physico-chemical properties | 34 |
| 7.9.9. Selection of the critical DNEL(s)/DMEL(s) and/or qualitative/semi-quantitative descriptors for critical health effects..... | 34 |
| 7.9.10. Conclusions of the human health hazard assessment and related classification and labelling | 34 |
| 7.10. Assessment of endocrine disrupting (ED) properties..... | 35 |
| 7.10.1. Endocrine disruption – Environment | 35 |
| 7.10.2. Endocrine disruption - Human health | 35 |
| 7.10.3. Conclusion on endocrine disrupting properties (combined/separate)..... | 35 |
| 7.11. PBT and VPVB assessment | 35 |
| 7.12. Exposure assessment | 35 |
| 7.12.1. Human health | 35 |
| 7.12.2. Environment | 36 |
| 7.12.3. Combined exposure assessment..... | 38 |
| 7.13. Risk characterisation..... | 38 |
| 7.13.1. Environment | 38 |
| 7.13.2. Human health | 38 |
| 7.14. References | 39 |
| 7.15. Abbreviations..... | 42 |

Part A. Conclusion

1. CONCERN(S) SUBJECT TO EVALUATION

Carbon tetrachloride (CCl₄) was originally selected for substance evaluation in order to clarify concerns about:

- potential mutagenicity, carcinogenicity and/or reprotoxicity;
- exposure of workers with a high aggregated tonnage even if only industrial use was reported (most of it as isolated intermediate or transported isolated intermediate).

2. OVERVIEW OF OTHER PROCESSES / EU LEGISLATION

CCl₄ is regulated under Regulation (EC) No 1005/2009 of the European Parliament and of the Council on substances that deplete the ozone layer (OJ L 286, 31.10.2009, p. 1) which prohibits its use except as an intermediate, industrial processing agent and laboratory agent.

3. CONCLUSION OF SUBSTANCE EVALUATION

CCl₄ was included in the Community rolling action plan (CoRAP) for substance evaluation pursuant to Article 44(2) of the REACH Regulation to be evaluated in 2012. CCl₄ was originally selected for substance evaluation in order to clarify concerns about mutagenicity, carcinogenicity, reprotoxicity and occupational exposure (considering high aggregated tonnages). During the evaluation, an additional concern has been identified with regard to the waiving of two-generation study.

As a result of substance evaluation, CCl₄ is not considered by eMSCA as a direct genotoxic agent, unless very high doses are used. DNA damages can be due to reactive oxygen species (ROS) and/or lipid peroxidation or related to a cytotoxic response since genotoxic effect was only observed at dose high where hepatic cytotoxicity occurred. The role of postulated reactive metabolites (including aldehydes, trichloromethyl or trichloromethylperoxyl free radicals, phosgen) in DNA damage was also hypothesized.

In conclusion, CCl₄ is considered to act as a carcinogen with threshold. The underlying carcinogenic mode of action is not clearly known. It is hypothesised that CCl₄ is metabolized by CYP2E1 into radicals or other reactive species leading to lipid peroxidation with associated cell cytotoxicity / proliferation (Anses, 2017).

There are still some uncertainties related to potential reproductive toxicity due to contradictory data and low relevance of the available studies. However, given the current tonnages and uses of the substance and the risk management measures which should be already in place, considering the known toxicity of the substance, these uncertainties alone do not substantiate a potential risk to be addressed under substance evaluation. This substance evaluation can be concluded without a request for further information.

ECHA has checked the compliance with the standard information requirements under REACH for reproductive toxicity and considered it compliant at the currently registered tonnage levels. However, if the registered tonnage increases in future, the eMSCA recommends ECHA to consider this substance for prioritisation for compliance check.

Regarding occupational exposure, OELs recommended by the SCOEL (2009) could be used by registrants. Exposure data provided in registration dossier (both modelled and measured) do not exceed OELs recommended by SCOEL.

The evaluation of the available information on the substance has led the evaluating Member State to the following conclusions, as summarised in the table below.

Table 1

| CONCLUSION OF SUBSTANCE EVALUATION | |
|---|-----------------|
| Conclusions | Tick box |
| Need for follow-up regulatory action at EU level | x |
| Harmonised Classification and Labelling | x |
| Identification as SVHC (authorisation) | |
| Restrictions | |
| Other EU-wide measures | |
| No need for regulatory follow-up action at EU level | |

4. FOLLOW-UP AT EU LEVEL

4.1. Need for follow-up regulatory action at EU level

As CCl₄ is regulated under Regulation (EC) No 1005/2009 on substances that deplete the ozone layer, there is no identified consumer uses.

Regarding reproductive toxicity, there are still some uncertainties related to the potential effects on fertility due to contradictory data and the low relevance of the available studies, however given the current tonnage and uses of the substance, clarification of these uncertainties is not considered a priority and therefore this substance evaluation can be concluded without a request for further information.

ECHA has checked the compliance with the standard information requirements under REACH for reproductive toxicity and considered it compliant at the currently registered tonnage levels. However, if the registered tonnage increases in future, the eMSCA recommends ECHA to consider this substance for prioritisation for compliance check.

4.1.1. Harmonised Classification and Labelling

CCl₄ has the following harmonised classification:

- Acute Tox. 3* - H301, H311, H331
- Carc. 2 - H351
- STOT RE 1 - H372**
- Aquatic Chronic 3 - H412
- Ozone 1 - H420

The registrants added the following classification:

- Skin Sens. 1B - H317

The following hazard classes are in addition notified among the aggregated self-classifications in the C&L Inventory:

- Acute Tox. 2 – H310
- Skin Irrit. 2 – H315
- Eye Irrit. 2 – H319
- Carc. 1B – H350
- Repr. 2 – H361

After the evaluation of available data, eMSCA considers that the current EU harmonised classification of CCl4 could be updated for the following endpoints:

- Add Skin Sens 1B – H317
- Change Carc 2 – H351 to Carc 1B –H350
- Change Acute Tox. 3 to Acute Tox. 4

4.1.2. Identification as a substance of very high concern, SVHC (first step towards authorisation)

Not considered at this stage.

4.1.3. Restriction

Not considered at this stage.

4.1.4. Other EU-wide regulatory risk management measures

Not considered at this stage.

5. CURRENTLY NO FOLLOW-UP FORESEEN AT EU LEVEL

Not applicable.

6. TENTATIVE PLAN FOR FOLLOW-UP ACTIONS (IF NECESSARY)

Indication of a tentative plan is not a formal commitment by the evaluating Member State. A commitment to prepare a REACH Annex XV dossier (SVHC, restrictions) and/or CLP Annex VI dossier should be made via the Registry of Intentions.

Table 3

| FOLLOW-UP | | |
|-------------------------|---|--------------|
| Follow-up action | Date for intention | Actor |
| CLH report | 2021- Scientifically justified but prioritisation criteria under considerations | France |

Part B. Substance evaluation

7. EVALUATION REPORT

7.1. Overview of the substance evaluation performed

CCl4 was originally selected for substance evaluation in order to clarify concerns about:

- mutagenicity, carcinogenicity, reprotoxicity,
- and exposure of workers with a high aggregated tonnage.

During the evaluation another concern was identified:

- waiving of two-generation study.

Table 4

| EVALUATED ENDPOINTS | |
|----------------------------------|---|
| Endpoint evaluated | Outcome/conclusion |
| Acute toxicity | Current harmonized classification as Acute Tox 3* Proposal to update as Acute Tox 4 - H332: harmful if inhaled |
| Corrosion / irritation | No further action |
| Skin / respiratory sensitisation | Proposal to add Skin Sens. 1B – H317 No concern identified for respiratory sensitisation |
| Repeated-dose toxicity | Liver identified as the most sensitive target organ. Current harmonized classification: STOT RE 1 - H372 (SCL = 1 %) after direct translation from the classification agreed under Directive 67/548/EEC. An update of this classification can be foreseen to add the route of exposure (oral; inhalation) and the target organ (liver) |
| Genotoxicity | Initial concern clarified. Not genotoxic: no further action |
| Carcinogenicity | Current harmonized classification as Carc. 2 Proposal to update as Carc. 1B – H350. As a result of substance evaluation, CCl4 is not considered by eMSCA as a direct genotoxic agent, unless very high doses are used. DNA damages can be due to ROS and/or lipid peroxidation or related to a cytotoxic response since genotoxic effect was only observed at dose high where hepatic cytotoxicity occurred. The role of postulated reactive metabolites (including aldehydes, trichloromethyl or |

| | |
|--------------------------|--|
| | <p>trichloromethylperoxyl free radicals, phosgen) in DNA damage was also hypothesized.</p> <p>In conclusion, CCl₄ is considered to act as a carcinogen with threshold. The underlying carcinogenic mode of action is not clearly known. It is hypothesized that CCl₄ is metabolized by CYP2E1 into radicals or other reactive species leading to lipid peroxidation with associated cell cytotoxicity / proliferation (Anses, 2017).</p> |
| Toxicity to reproduction | <p>There was not sufficient information to conclude on the integrity and performance of the male and female reproductive systems, and the effect on neonatal and postnatal developmental toxicity. Therefore there are still some uncertainties related to potential reproductive toxicity. However given the current tonnages and uses of the substance and the risk management measures which should be already in place, considering the known toxicity of the substance, these uncertainties alone do not substantiate a potential risk to be addressed under substance evaluation. This substance evaluation can be concluded without a request for further information.</p> <p>Prenatal developmental toxicity: no further action.</p> |

Regarding exposure scenarios, eMSCA identified inconsistencies in the chemical safety assessments provided by the registrants as mentioned in section 7.12.1.1 and detailed in the confidential annex, regarding the choice of some exposure concentrations for workers and the inhalation DNEL chosen for risk characterisation. Clarifications are needed from the registrants.

7.2. Procedure

CCl₄ was included in the Community rolling action plan (CoRAP) for substance evaluation pursuant to Article 44(2) of the REACH Regulation to be evaluated in 2012. CCl₄ was originally selected for substance evaluation in order to clarify concerns about mutagenicity, carcinogenicity, reprotoxicity and occupational exposure (considering high aggregated tonnages). During the evaluation, an additional concern has been identified with regard to the waiving of two-generation study. Indeed, at this time issue on CCH was to be sorted out during substance evaluation.

Following substance evaluation, a Decision dated 26 February 2014 requested the registrants to conduct an Extended One Generation Reproduction Toxicity Study by inhalation route (test method: OECD443). Specific Decisions were also addressed to some registrants regarding exposure scenarios (occupational and environmental exposure).

Regarding the main Decision, the Board of Appeal annulled the Agency's Decision on the substance evaluation of CCl₄ the 23rd of September 2015 (case number A-005-2014). The Board of Appeal found that the Contested Decision was disproportionate on the grounds that an EOGRTS was not necessary to clarify a risk to

human health or the environment. In addition, the Agency had not adequately justified requesting information under substance evaluation, which was standard information requirement for one of the registrants under the REACH Regulation.

As a result of the specific Decisions regarding exposure scenarios, chemical safety reports have been updated by the main registrants in June 2016. Registered tonnage has been downgraded.


7.3. Identity of the substance

Table 5

| SUBSTANCE IDENTITY | |
|--|----------------------|
| Public name: | Carbon tetrachloride |
| EC number: | 200-262-8 |
| CAS number: | 56-23-5 |
| Index number in Annex VI of the CLP Regulation: | 602-008-00-5 |
| Molecular formula: | CCl ₄ |
| Molecular weight range: | 153.8227 |
| Synonyms: | tetrachloromethane |

Type of substance ☒ Mono-constituent ☐ Multi-constituent ☐ UVCB

Structural formula:



The substance is considered, according to compositions submitted by the registrants, as monoconstituent according to REACH guidance for identification and naming of substances except for one composition considered by eMSCA as a multi-constituent substance (confidential annex).

Different manufacturing processes exist. They are based on the same chemical reaction but conditions (initiation, pressure, temperature...) and reactants differ. Moreover a purification step is performed or not, leading to different impurity profiles and different classifications of the substance (confidential annex).

Three registrants did provide analytical informations (UV/VIS, IR, NMR and GC chromatograms) to confirm the compositions and the structure of their registered substances. However, three registrants were not providing analytical data in their dossiers (confidential annex).

7.4. Physico-chemical properties

Table 7

| OVERVIEW OF PHYSICOCHEMICAL PROPERTIES | |
|---|--|
| Property | Value |
| Physical state at 20°C and 101.3 kPa | <p>Value used for CSA: liquid at 20°C and 101.3 kPa</p> <p>Data is available in a peer reviewed handbook (Merck Index 2006). Data is available in literature which gives a consistent result.</p> |
| Vapour pressure | <p>Value used for CSA: 12046 Pa at 19.8 °C</p> <p>Data are available in a peer-reviewed handbook : 15.2 kPa at 25°C (CRC Handbook, 2009) and in a well described publication : 12046 Pa at 19.8°C and 14549 Pa at 24°C (Boublik, 1972). These values are consistent.</p> <p>Another supportive data from Handbook (Ullmann, 2002) gives a value of 11940 Pa at 20°C. This value has the same order of magnitude. Slight difference may be due to the difference of purity of the test material and to the accuracy of method used which are not specified.</p> <p>Carbon tetrachloride is volatile.</p> |
| Water solubility | <p>Value used for CSA: 846.1 mg/L at 20 °C</p> <p>A data has been generated according to OECD guideline 105 and GLP requirements which give a value of 846.1 mg/L at 20°C.</p> <p>The data reported in CRC Handbook (0.65 g/L at 25°C) has the same order of magnitude as the value generated in the study. Slightly difference may be due to the difference of purity of the test material, the difference of pH and to the accuracy of method used which is not specified.</p> <p>Carbon tetrachloride is moderately soluble.</p> |
| Partition coefficient n-octanol/water (Log Kow) | <p>Value used for CSA: Log Kow (Pow): 2.83 at 25 °C</p> <p>The reliability of 2 in the Klimisch scale is to be granted to the two peer reviewed experimental Handbook data being 2.64 and 2.83. The former used for the CRC handbook, which can, according to ECHA guidance, be regarded as peer reviewed, and the latter originally reported from Hansch et al (1995) and used for the training set of the validated QSAR software KOWWIN™ from the U.S. EPA EPI suite 4.0 package.</p> <p>A further experimental value of 2.75 at 23°C (Huels 1989) fits in the same range.</p> <p>The recommended value is logKow = 2.83</p> |

| OVERVIEW OF PHYSICOCHEMICAL PROPERTIES | |
|---|---|
| Property | Value |
| Flammability | <p>Value used for CSA: non flammable</p> <p>Carbon tetrachloride is a liquid at room temperature thus its primary value for ease of ignition is the flash point. In addition, based on experience in handling, carbon tetrachloride is not pyrophoric and is not flammable on contact with water.</p> |
| Explosive properties | <p>Value used for CSA: non explosive</p> <p>The substance does not contain any functional groups associated with explosive properties.</p> |
| Oxidising properties | <p>Value used for CSA: non oxidizing properties</p> <p>The substance does not contain any functional groups associated with oxidising properties</p> |
| Granulometry | Not relevant. Carbon Tetrachloride has a melting point of -22.62 °C at 1013.25 hPa and therefore is a liquid at normal ambient temperatures. |
| Stability in organic solvents and identity of relevant degradation products | A study on the stability of carbon tetrachloride is not required as the stability of carbon tetrachloride in organic solvents is not regarded as critical. |
| Dissociation constant | The substance does not contain any relevant functional groups |
| Melting/freezing point | <p>Value used for CSA: -22.62 °C at 101.3 kPa</p> <p>A study on the melting point/freezing point does not need to be conducted below a lower limit of -20°C. Available data from a peer-reviewed handbook (CRC Handbook, 2009) reports a melting point of -22.62°C at 1013.25 hPa. This value is in good agreement with the value (-22.99°C) found in an old publication (Dreisbach, 1949). Moreover these values are consistent with the Merck Index (2006) value which is -23°C.</p> |
| Boiling point | <p>Value used for CSA: 76.8 °C at 101.3 kPa</p> <p>Data is available in a peer reviewed handbook (CRC Handbook, 2009) and gives a boiling point of 76.8°C. The value given is in line with a value (76.75°C) found in the literature (Dreisbach, 1949). These two values are consistent with the Merck Index (2006) value which is 76.7°C.</p> |
| Relative density | <p>Value used for CSA: 1.59 at 20°C</p> <p>Data for several temperatures are available in a peer-reviewed handbook (CRC Handbook, 2009). These values are in line with the density of 1594.7 kg/m³ reported in another handbook at 20 °C (Ullmann's, 2002) and the relative density of 1.59 at 20/4°C found in an old publication (Dreisbach, 1949) and the relative density found in the Merck</p> |

| OVERVIEW OF PHYSICOCHEMICAL PROPERTIES | |
|--|--|
| Property | Value |
| | Index (2006): 1.589. Thus the density of the substance is found to be 1.59 g/cm ³ at 20°C. |
| Solubility in organic solvents | Value used for CSA: soluble in acetone and ethanol Data is available in a peer reviewed handbook (CRC Handbook, 2009) |
| Surface tension | An available publication reports a surface tension of 26.92 mN/m at 20°C for pure carbon tetrachloride. This value is in good agreement with the value found in an handbook and in another publication (26.7 mN/m at 20°C). |
| Viscosity | Value used for CSA: 0.7676 mPa.s at 40°C; 0.9575 at 25°C A detailed publication is available: the viscosity is reported to be 0.7676 mPa.s at 40°C and 0.9575 at 25°C. Value found in a peer-reviewed handbook (CRC Handbook of Chemistry and Physics): 0.908 mPa.s at 25 °C is consistent with the value provided in the publication. An Handbook (Ullmann) reports a viscosity of 1.35 mPa.s at 20°C. Slight difference may be due to the difference of purity of the test material and to the accuracy of method used which are not specified. |

7.5. Manufacture and uses

7.5.1. Quantities

Table 8

| AGGREGATED TONNAGE (PER YEAR) | | | | |
|---|--|---|---|--|
| <input type="checkbox"/> 1 – 10 t | <input type="checkbox"/> 10 – 100 t | <input type="checkbox"/> 100 – 1000 t | <input checked="" type="checkbox"/> 1000- 10,000 t* | <input type="checkbox"/> 10,000-50,000 t |
| <input type="checkbox"/> 50,000 – 100,000 t | <input type="checkbox"/> 100,000 – 500,000 t | <input type="checkbox"/> 500,000 – 1000,000 t | <input type="checkbox"/> > 1000,000 t | <input type="checkbox"/> Confidential |

There are 8 active registrants according to ECHA dissemination website (accessed on January 2019).

*During the compliance check performed by ECHA, the registered tonnage band of some registrants was downgraded so that at this point in time there are no full registrations ≥ 1000 tpa.

7.5.2. Overview of uses

Table 9

| USES | |
|------------------------------|--|
| | Use(s) |
| Uses as intermediate | Use as chemical intermediate |
| Formulation | / |
| Uses at industrial sites | Use as a process agent / solvent according to Annex III of Regulation (EC) 1005/2009 |
| Uses by professional workers | / |
| Consumer Uses | / |
| Article service life | / |

CCl₄ is regulated under Regulation (EC) No 1005/2009 on substances that deplete the ozone layer, which prohibits its use except as an intermediate, industrial processing agent and laboratory agent.

7.6. Classification and Labelling

7.6.1. Harmonised Classification (Annex VI of CLP)

Table 10: Harmonised classification – as stated by Regulation No 286/2011 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008

| HARMONISED CLASSIFICATION ACCORDING TO ANNEX VI OF CLP REGULATION (REGULATION (EC) 1272/2008) | | | | | | | |
|--|--|-----------|---------|-----------------------------------|--------------------------|---|-------|
| Index No | International Chemical Identification | EC No | CAS No | Classification | | Spec. Conc. Limits, M-factors | Notes |
| | | | | Hazard Class and Category Code(s) | Hazard statement code(s) | | |
| 602-008-00-5 | carbon tetrachloride tetrachloromethane | 200-262-8 | 56-23-5 | Acute Tox. 3* | H301 | | |
| | | | | Acute Tox. 3* | H311 | | |
| | | | | Acute Tox. 3* | H331 | | |
| | | | | Carc. 2 | H351 | | |
| | | | | STOT RE 1 | H372** | | |
| | | | | | | STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: ,2 % ≤ C < 1 % | |

| HARMONISED CLASSIFICATION ACCORDING TO ANNEX VI OF CLP REGULATION (REGULATION (EC) 1272/2008) | | | | | | | |
|--|---------------------------------------|-------|--------|-----------------------------------|--------------------------|-------------------------------|-------|
| Index No | International Chemical Identification | EC No | CAS No | Classification | | Spec. Conc. Limits, M-factors | Notes |
| | | | | Hazard Class and Category Code(s) | Hazard statement code(s) | | |
| | | | | Aquatic Chronic 3 | H412 | | |
| | | | | Ozone 1 | H420 | | |

7.6.2. Self-classification

- In the registration(s):

Skin Sens. 1B - H317

- The following hazard classes are in addition notified among the aggregated self-classifications in the C&L Inventory:

AcuteTox. 2 – H310

Skin Irrit. 2 – H315

Eye Irrit. 2 – H319

Carc. 1B – H350

Repr. 2 - H361

7.7. Environmental fate properties

7.7.1. Degradation

Hydrolysis

All submitted studies are considered as supporting data. Nevertheless, based on the weight of evidence, they indicate that hydrolysis is not a relevant process for the degradation of CCl₄ under environmental conditions.

Phototransformation/photolysis

Estimates of the atmospheric lifetime (the overall persistence of CCl₄ in the troposphere and the stratosphere combined) range from 30 to 100 years, with 50 years (i.e. 18,250 days) generally being accepted as the most reasonable value. The atmospheric lifetime of CCl₄ is assigned to 50 years.

CCl₄ dissolved in water does not photodegrade in any measurable amounts. The carbon atom in CCl₄ is in its most oxidized state; therefore it is much more likely to undergo reductive degradation. It may undergo reductive dechlorination in aquatic systems in the presence of free sulfide and ferrous ions.

Biodegradation

In water, under aerobic conditions, a negative result (0% biodegradation in 14 days) has been reported for a ready biodegradability test according to OECD TG 301 C (MITI(I) test method). However, toxicity to bacteria may have prevented biodegradation at the high concentration used in the test (30 mg/l) so the study is considered to be unreliable. In an article reporting biodegradation studies on US priority chemicals, it was observed a rapid primary biodegradation at 5 and 10 mg/L under aerobic conditions (Tabak et al, 1981; Bunch et al, 1967).

Under anaerobic conditions, several studies have reported metabolization and mineralisation of CCl₄ and it can be concluded that it is rapidly biodegradable in the corresponding compartments, as well as in digesters.

In view of the limited evidence for biodegradation in aerobic (oxidative) conditions but the observed mineralisation in anaerobic (reductive) conditions, it is proposed to conclude that CCl₄ is inherently biodegradable, not fulfilling criteria for the risk assessment.

7.7.2. Environmental distribution

Adsorption/desorption

The mean K_{oc} values from 7 determinations in 2 soils were 143.6±32.11 for the silt loam and 48.9±16.16 for the sandy loam, while the weighted mean K_{oc} value for both soils was calculated being 115.2.

Volatilisation

The value used for risk assessment is an Henry's law constant (H) at 20°C of 2370 (in Pa m³/mol or dimensionless). These data indicates that CCl₄ partitions easily from water to air.

7.7.3. Bioaccumulation

Several experimental determinations of BCF have been carried out on freshwater fish species. Only one of them is reported with enough details to be used in this assessment. Other data exist on fish or algae but too few experimental information is available to use these studies in the present assessment. A data on QSAR is also given and shows a correlation with data obtained in the key study.

Low bioconcentration factors have been measured in aquatic species. In freshwater fish, the BCF has been measured and documented in rainbow trout (BCF = 40) and bluegill sunfish (BCF = 30).

7.8. Environmental hazard assessment

7.8.1. Aquatic compartment (including sediment)

7.8.1.1. Fish

The lowest value for the short term toxicity is observed in a study using zebrafish *Brachydanio rerio* (OECD TG 203), with a LC₅₀ (96 h) of 24.3 mg/L.

For the long term toxicity, the value is based on the effect observed at the lowest concentration in a study considered to be reliable using zebrafish *Brachydanio rerio* in a 14

days prolonged toxicity test using a flow-trough system. This protocol is not considered as a true chronic test but rather a subchronic one. The derived NOEC was 2.5 mg/L.

A second study (Black, 1992) using rainbow trout and fathead minnow in short term toxicity tests on embryo and 'sac fry' stages is considered unreliable. This study has been criticised for testing widely spaced concentrations and giving few details of control performance and the methods were non-standard and not well validated. However, they were conducted under flow-through conditions, with control of volatile loss and with concentration analysis. Therefore, the long-term LC50 values should not be used for endpoint derivation. The 9 day-LC50 (4 days post-hatch) for *P. promelas* was 4 mg/l; for *S. gairdneri*, the 27 day-LC50 (4 days post-hatch) was 1.97 mg/l. The lowest concentration tested which had no discernible effect on survival of *S. gairdneri* (0.07 mg/l) is not valid as a NOEC, because of the wide interval between concentrations. The conclusion of the study is that the apparent NOEC was within the range 0.07 to 1.1 mg/l. However, the lower end of this range is approximately the same than the NOEC for freshwater algae. Therefore, the *S. gairdneri* study is sufficient to demonstrate that fish are no more sensitive than other trophic levels and the study can be used for that purpose without needing to define a NOEC for PNEC calculation.

7.8.1.2. Aquatic invertebrates

There is no fully reliable study available to assess the acute toxicity of CCl₄ on daphnia. There is a *weight of evidence* that the EC50-48h must be in the range 10 to 100 mg/L, based on the majority of studies submitted in the registration dossier. The data published by the Japanese Ministry of the Environment (EC50-48h of 8.1 mg/L) seems below this range and should be considered with caution since, in a reliable chronic toxicity study, no mortality was observed among parent animals, during 21 days up to the highest tested concentration of 5.7 mg/L (measured). The measured NOEC is 3.1 mg/L. Moreover, there is not enough detail to validate the data published by the Japanese Ministry of the Environment.

Consequently, eMSCA uses the lowest concentration for the short-term toxicity to aquatic invertebrates: EC50 (48h) = 35 mg/L for daphnia, static (OECD TG 202).

The concentration used for the long term toxicity is based on a compliant and well conducted GLP OECD 211 study using *Daphnia magna* in a semi static 21 days reproduction test. Both growth and reproduction endpoints yielded the same values for NOEC (3.1 mg/L) and LOEC (5.7 mg/L).

7.8.1.3. Algae and aquatic plants

In order to take into account the volatility of the substance, an adapted algae experiment on *P. subcapitata* (OECD 201 compliant study) was carried out in stoppered flasks with no headspace, and using a medium buffered with HEPES in order to avoid pH drift. Good recovery of the test substance was demonstrated through analytical measurement (GC/MS) and other validity criteria were met. Consequently the values obtained in this study can be retained as reliable to assess algae toxicity: ErC50-72 = 20 mg/L, ErC10-72 = 6.3 mg/L and NOErC = 2.2 mg/L.

7.8.1.4. Sediment organisms

Due to its high volatility and its low adsorption properties, eMSCA considers negligible the risk of CCl₄ to sediment.

7.8.2. Terrestrial compartment

Due to its high volatility and its low adsorption properties, eMSCA considers negligible the risk of CCl₄ to soil organisms.

However, a PNEC value was calculated based on the aquatic toxicity with the equilibrium partitioning method.

7.8.3. Microbiological activity in sewage treatment systems

Inhibition of growth of cultures of *Pseudomonas putida* shows that the threshold of toxicity is 30 mg/L (BRINGMANN-G/KUHN-R, 1980b). This threshold of toxicity can be used in place of a NOEC.

7.8.4. PNEC derivation and other hazard conclusions

Table 11

| PNEC DERIVATION AND OTHER HAZARD CONCLUSIONS | | |
|---|-----------------------------------|---|
| Hazard assessment conclusion for the environment compartment | Hazard conclusion | Remarks/Justification |
| Freshwater | PNEC aqua (freshwater): 0.22 mg/L | Assessment factor: 10 Extrapolation method: assessment factor PNEC value is derived from the lowest long toxicity endpoint available for the most sensitive species: NOErC = 2.2 mg/L on <i>P. subcapitata</i> |
| Sediments (freshwater) | Not relevant | Due to the high volatility of CCL4 and its low adsorption properties, the risk for sediment toxicity to be inflicted by CCL4 is regarded negligible |
| Sewage treatment plant | PNEC STP: 30 mg/L | Assessment factor: 1 Extrapolation method: assessment factor PNEC value is derived from the available study on <i>S. putida</i> : NOEC = 30 mg/L |
| Soil | PNEC soil : 0.45 mg/kg ww | Extrapolation method: Equilibrium partitioning method based on the PNEC aqua |
| Secondary poisoning | Not relevant | Considering the low potential for bioaccumulation of CCL4, the risk for secondary poisoning is regarded negligible |

7.9. Human Health hazard assessment

7.9.1. Toxicokinetics

The water solubility (846.1 mg/L), the log Kow value (2.83) and the small size (153.82 g/mol) of CCl₄ are favourable to absorption.

Most of following data come from the ATSDR Toxicological Profile of CCl₄ (2005).

Absorption: CCl₄ is readily absorbed from gastrointestinal and respiratory tracts, and more slowly through skin.

Results from animal studies indicate a gastrointestinal absorption of at least 85%. Influence of the vehicle used is noted with rapid and extensive absorption when water or other aqueous vehicles are used compared to corn oil (ATSDR, 2005).

The dermal absorption rate is 53.6 ± 9.30 nmol/min/cm² for the mouse (Tsuruta et al., 1975) and 1.246 μ mol/min/cm² for the rat (Morgan et al., 1991).

By inhalation, the absorption across the lung was estimated to be about 60% in humans (ATSDR, 2005). CCl₄ is absorbed readily in male rats (Sanzgiri et al., 1997).

Distribution: CCl₄ is distributed in all organs. Because of its lipophilic properties, CCl₄ mainly accumulates in fat-rich tissues (adipose tissue, liver, bone marrow, brain and kidney) (ATSDR, 2005; Sanzgiri et al., 1997).

In spite of its physico-chemical properties, the substance is not expected to have a bioaccumulation potential since half-lives in organs are comprised between 4 and 12 hours.

Metabolism: About 50% of CCl₄ is metabolised (ANSES, 2017). CCl₄ was mainly metabolized by cytochrome P-450 enzymes (CYP 2E1 and CYP3A), with the production of the trichloromethyl radical (CCl₃*). This radical can be fixed in particular to lipids thus altering their metabolism or form DNA adducts.

Excretion: CCl₄ is primarily excreted in exhaled air and in the faeces, relatively minimal amounts in the urine. Excretion of CCl₄ and its metabolites may vary by species, dose and route of exposure. Forty eight hours after 4h-nose-only inhalation, rats, mice and hamsters eliminated 65-83% of the initial body burden as CO₂ or volatile organic compounds in exhaled air (ATSDR, 2005).

7.9.2. Acute toxicity and Corrosion/Irritation

Acute toxicity:

Data are of low quality for acute toxicity by oral, inhalation and dermal exposure.

The acute oral, dermal and inhalation toxicity of CCl₄ in rodents is mainly based on systemic effects in the liver (centrilobular necrosis) and some effects on the kidney. The lowest LD₅₀ reported after oral and dermal administrations were about 2000 mg/kg bw. By inhalation, the LC₅₀ are reported to be about 7000 ppm.

In humans, the main effects observed are depression of the central nervous system, hepatic disorders progressing to hepatic insufficiency (liver failure) and renal damage that may progress to reversible renal tubulopathy. These effects are observed regardless of the route of exposure. However, inhalation is the main route of exposure in the intoxications or accidents reported in the literature. Local effects are also reported after accidental or voluntary poisoning by the oral route and after dermal exposure.

This substance is currently classified according to CLP Regulation for acute oral, dermal and inhalation toxicities as followed:

Acute tox 3*

- H331: toxic if inhaled
- H311: toxic in contact with skin
- H301: toxic if swallowed

This classification is a direct translation from the classification agreed under Directive 67/548/EEC to CLP Regulation (CLP00).

Following substance evaluation, and though it is noted by eMSCA that this endpoint is not of high priority, eMSCA proposed to modify the classification regarding Acute toxicity as :

- Acute tox 4 H332: harmful if inhaled.

Corrosion / irritation

The data available are of low quality. Slight skin or eye irritations were reported in guinea pigs and rabbits.

In humans, gastric irritations have been reported following accidental or voluntary poisoning by the oral route. CCl₄ causes the formation of transient erythema via dermal route.

7.9.3. Sensitisation

The potential of CCl₄ to induce skin sensitisation was evaluated using the murine Local Lymph Node Assay (LLNA) (unpublished study report, 2010).

A dose-related increase in the SI (stimulation index) was noted at all the concentrations (25 %: SI = 1.51; 50 %: SI = 2.39; 100%: SI =6.10).

In the absence of local irritation, the positive lymphoproliferative response observed was attributed to delayed contact hypersensitivity. The EC₃ value for CCl₄ was equal to 58%.

Therefore, on the basis of this LLNA assay, CCl₄ should be classified as skin sensitizer category 1B according to CLP regulation EU No. 286/2011. An update of the harmonised classification should be initiated.

7.9.4. Repeated dose toxicity

Repeated dose toxicity, oral:

No reliable study in humans was identified.

Many animal studies were available. All the studies were considered of reliability 3 or 4. None of them was performed according to GLP nor other official current guideline (Bruckner et al., 1986; Condie et al., 1986; Hayes et al., 1986; Koporec et al., 1995).

The lowest relevant NOAEL identified (NOAEL = 1 mg/kg bw /day) was based on effects observed in the liver of male rats at 10 mg/kg bw/day (Bruckner et al., 1986). Only a limited number of parameters were tested in comparison with the OECD TG 408. In this study, male rats were treated by gavage 5 days/week with 1, 10, 33 mg/kg bw of CCl₄ in corn oil during 12 weeks. Three parameters of liver injury (OCT (ornithine carbamyl

transferase) activity, SDH (sorbitol dehydrogenase) activity and GPT (glutamic-pyruvic transaminase) activity) and one for kidney injury (blood urea nitrogen) were determined in addition to histopathology of liver and kidney. Slight but statistically significant increase of SDH value and mild hepatic centrilobular vacuolization were observed at 10 mg/kg bw. In the high dose group marked hepatotoxicity was noted including vacuolization, nuclear and cellular pleomorphism, bile duct hyperplasia and periportal fibrosis.

The other studies available support the above finding.

Condie et al. (1986) reported a similar NOAEL of 1.2 mg/kg bw/day when mice were exposed by gavage to CCl₄ in corn oil at dose levels of 1.2, 12 or 120 mg/kg bw for 90 days (5 days/week). The primary target organ was the liver with fatty change as first noticeable effect followed by central lobular degeneration, fibrosis and finally cirrhosis. Liver toxicity was also apparent due to the rise of classical biochemical parameters (AST (aspartate aminotransferase), ALT (alanine aminotransferase), AP (alkaline phosphatase), SDH, LDH (lactate dehydrogenase), etc.).

Hayes et al. (1986) also identified liver as the most sensitive target organ in mice exposed by gavage. Indeed, effects on clinical chemistry were reported at all tested doses (between 12 to 1200 mg/kg bw/day for 13 weeks). In addition, the kidneys, thymus and spleen were identified as other target organs based on relative and absolute organ weight.

Similar findings were observed by Koporec et al. (1995) at all tested doses (25 or 100 mg/kg bw) of CCl₄ administered by gavage for 90 days in male rats.

Finally, Kutepov et al. (1968) stated a NOAEL of 0.15 mg/kg bw/day and a LOAEL of 1.5 mg/kg bw/day for rats exposed orally for 6 months, based on biochemical parameters (AST, ALT) and determination of liver excretion function. But this 6-month study presented some major deficiencies: dose spacing between the doses was high and the LOAEL was very close to the NOAEL determined in the Bruckner et al. (1986) study, no information concerning the type of administration (gavage or diet), the number of animals, and no detailed result. The presented information was so limited that this study was judged unreliable.

Mechanism of toxicity

Liver and kidney are especially vulnerable to the toxicity of CCl₄ because of the abundance of CYP2E1 and various isoforms of CYP3A. Hepatic injury results from bioactivation of CCl₄ into free-radical metabolites of CCl₄ and lipid peroxidation.

Intrinsic tissue levels of antioxidants such as glutathione influence the degree to which oxidative damage progresses following exposure to CCl₄. Another factor that may be of importance in CCl₄-induced hepatotoxicity is the perturbation of normal cellular calcium homeostasis following exposure.

In conclusion, the NOAEL of 1 mg/kg bw/day from the Buckner et al. (1986) study is the most relevant value from the available studies considering the observed effects and the dose spacing.

Repeated dose toxicity, dermal:

No study was available for this endpoint.

Repeated dose toxicity, inhalation:

Several studies performed by inhalation are available for CCl₄. The most relevant data come from studies carried out by Nagano et al. in 2007.

In a 13-week study, carried out according to OECD guideline 413 and with a Klimisch score of 1, Nagano et al. (2007a) administered CCl₄ at 0, 10, 30, 90, 270 and 810 ppm (corresponding to 64, 192, 576, 1728 and 5184 mg/m³) by inhalation (whole body) 6 hours per day, 5 days per week to male and female rats and mice. The most sensitive endpoint is liver toxicity, including liver fatty change with large droplets found at all concentrations in both species, as well as an increased relative liver weight only in male rats. Enhanced cytolytic release of liver transaminase into plasma was observed at medium (30 and 90 ppm) and high levels (270 and 810 ppm) of exposure. At high exposure levels (270 and 810 ppm), altered cell foci in the liver, fibrosis and cirrhosis were observed.

It should be noted that these findings are relevant for humans as reported by Gluchowski NL 2017.

Nephrotoxicity was also observed: increased relative kidney weight (at dose \geq 90 ppm in male and female rats and at dose \geq 30 ppm in male mice and \geq 270 in female mice), increased urinary protein (in male rats at doses \geq 270 ppm and in female at doses \geq 90 ppm) and localized glomerulosclerosis in male and female rats exposed to 810 ppm.

Based on the effects reported at all concentrations in the liver, a NOAEC could not be derived; the LOAEC is 10 ppm (64 mg/m³).

The liver effects were preneoplastic lesions of hepatocarcinogenesis which were studied in the 2-year study performed by Nagano et al. (2007b). In this study, male and female rats and mice were exposed by inhalation to 0, 5, 25 and 125 ppm (0, 32, 160 and 800 mg/m³) of CCl₄ for 2 years, 6 hours per day, 5 days per week. This study was assigned with a Klimisch score of 2 (lack in reporting of experimental data but well conducted; further details on this study are reported in section 7.9.6 of this document).

In mice, a LOAEC of 25 ppm (160 mg/m³) and a NOAEC of 5 ppm (32 mg/m³) were determined, based on the increase of organ weights (liver and adrenal gland) and biochemical parameters indicative of liver toxicity.

For rats, increased urinary protein levels was observed in the low dose groups (5 and 25 ppm). The kidney toxicity (increase blood urea nitrogen (BUN), creatinine...) was reported at exposure concentration of 25 ppm and more. While the increased severity of proteinuria could be related to the nephropathy at \geq 25 ppm, the biological significance at 5 ppm was unknown. Proteinuria was found in essentially 100% of the rats (both control and CCl₄ exposed) and 90% or more of the rats had proteins in urine. However, in the exposed animals, rats showed an increase in the severity of proteinuria compared to controls. After 2 years of exposure, proteinuria in rats treated with 5 ppm, did not progress (rats did not show treatment related increases in incidence or severity of renal changes that were observed at higher exposure). Furthermore, the F344 rat is known for its high incidence of spontaneous, age-related chronic progressive nephropathy (CPN). Therefore, the relevance of the effect reported at 5 ppm remains questionable.

The toxicity of CCl₄ seems more influenced by the concentration than the duration of exposure as the LOAEC for systemic toxicity were in the same order of magnitude in the 90-day study and 2-year study of Nagano (2007 a & b).

Further studies, with low reliability, support the results reported by Nagano et al. (2007 a & b):

Smyth (1936) (Klimisch score: 4) reported effects of CCl₄ at all concentrations tested (from 25 ppm in guinea pigs with lactate treatment and from 50 ppm for rats, guinea pigs and monkeys) after exposure for 10.5 months 8h/d; 5d/w. Liver was identified as the most sensitive organ. In addition, granular swelling of the adrenals was observed in guinea pigs at 25 ppm and more.

The study of Adams (1952) presented a LOAEC of 10 ppm (64 mg/m³) in rats and guinea pigs for subchronic repeated dose toxicity via inhalation exposure during 15-25 weeks. This LOAEC was also based in fatty change in the liver and liver weight increase. The corresponding NOAEC was 5 ppm (32 mg/m³). However, a Klimisch score of 4 was assigned to this study as only a limited number of parameters were tested as compared to OECD TG413. Nevertheless this result was in line with the subchronic inhalation 90-day study of Nagano (2007a) and could be used as supportive data.

A LOAEC of 62 mg/m³ was identified after a subchronic continuous exposure to CCl₄ (24h/day, 7d/week, 13 weeks) based on fatty change in the liver and increase liver weight in rats (Mac Ewen et al., 1966 – Klimisch score: 4). No NOAEC can be derived.

The study of Prendergast (1967) (Klimisch score: 4) where rats, guinea pigs, rabbits and monkeys were exposed continuously (24h/day, 7d/week) for 90 days to 6.1 mg/m³ and 61 mg/m³ (0.95 and 9.5 ppm) of CCl₄ reported a NOAEC of 0.95 ppm based on fatty change in the liver and liver weight increase. This NOAEC can correspond to a value of 34.2 mg/m³ when converting this continuous exposure into an exposure of 6h/day; 5d/week as in the Nagano et al. (2007a) study. This is thus consistent with the NOAEC of 32 mg/m³ identified from the Nagano study (2007b).

A LOAEC of 63 ppm was derived in rats after a 4-week exposure to CCl₄; 6h/d; 7d/week based on fatty change in the liver, increased liver weight and biochemical findings (Bogers et al., 1987 – Klimisch score: 4). No NOAEC can be derived.

In conclusion, the most sensitive target organ of CCl₄ toxicity is the liver. In addition, CCl₄ has also a nephrotoxic potential at concentrations higher than those inducing hepatotoxicity (Nagano et al. 2007).

Human data:

Occupational exposure to unknown concentrations of CCl₄ vapor for periods between 6 weeks and 3 months resulted in gastro-intestinal effects (nausea, vomiting, abdominal pain, anorexia), hepatic effects (observed as jaundice), and neurological effects (headache, dizziness) (Norwood, 1950).

Kazantis (1960) described symptoms in 17 workers exposed to CCl₄ vapor at concentrations between 45 and 97 ppm, which were anorexia, nausea, vomiting, epigastric discomfort or distention, depression, irritability, headache, or giddiness. Symptoms typically occurred during the latter of the workweek and recovered at the end of week-end. One worker reporting these symptoms during a period of 2 years, had also an increased serum AST level.

Tomenson (1995) conducted a cross-sectional study of hepatic function in 135 CCl₄-exposed workers in 3 chemical plants and in a control group of 276 unexposed workers. Blood samples were analysed for ALT, AST, alkaline phosphatase, gamma-glutamyl transferase, glutamate dehydrogenase, 5'-nucleotidase, total bile acids, cholesterol, triglycerides and hematological variables. The quantitative exposure levels associated with each of these categories were: ≤1 ppm for "low", 1.1-3.9 ppm for "medium", 4-11.9 ppm for "high". Exposed workers were also categorized according to length of time in job (<1, 1-5, >5 years). Overall, this study provided suggestive evidence of an effect from occupational CCl₄ exposure on hepatic serum enzymes, indicating effects in human liver. Specifically, serum enzyme changes suggested an exposure-related effect in medium and high exposure categories. In the low exposure group, only the haematocrit was significantly decreased.

Classification:

The substance is currently classified according to CLP Regulation as STOT RE 1 (H372) with a specific concentration limit of 1 % after direct translation from the classification agreed

under Directive 67/548/EEC. Current harmonized classification should be updated to add the route of exposure (oral; inhalation) and the target organ (liver).

7.9.5. Mutagenicity

Many studies are available. However, a very limited number of these studies were conducted according to OECD guidelines and GLP. The data have been evaluated by different organisations (IARC, 1999; WHO, 1999; ATSDR, 2005; Afsset, 2009; US-EPA, 2010; Anses, 2017). Considering all the studies, it is possible to conclude by a *weight of evidence* approach that this substance is not genotoxic.

Genetic toxicity in *in vitro* microbiological systems:

The majority of mutagenicity assays for bacteria exposed to CCl₄ gave negative results with or without metabolic activation, but volatilization of the chemical in standard plate incorporation methods using unsealed plates may have contributed to some negative findings.

In conclusion, positive slight effects were only observed at high dose and in particular in *E. Coli* strains which are more sensitive to oxidative mutagens (EPA, 2010; SCOEL, 2009).

Genetic toxicity in *in vitro* mammalian cell systems:

Various authorities (ATSDR 2005, EPA 2010, ANSES, 2017) reach similar conclusions regarding the *in vitro* tests in mammalian cells: some tests were positive, some were negative, some were ambiguous. In most of the positive tests, the effects can be explained more likely by oxidative DNA damage, secondary to cytotoxicity of CCl₄.

In 2010, the EPA concluded that under certain conditions, CCl₄ can induce genotoxic effects in mammalian cells exposed *in vitro*. Multiple studies indicated that at high dose, bioactivated CCl₄ was able to cause DNA breaks leading, in some cases, to chromosome breakage. Multiple studies indicated that CCl₄ was able to interfere with chromosome segregation resulting in modest levels of chromosome loss and aneuploidy. Both specific and non specific mechanisms were envisaged. In most tests with positive results, genotoxic effects were observed with significant toxicity.

Genetic toxicity in *in vivo* cell systems:

In general, studies analysing genotoxic effects of CCl₄ with established methods (Suzuki 1997, Foureman 1994, Sawada 1991, Sasaki 1998, Barbin 1982, Bermudez 1982, Mirsalis 1982, Stewart, 1981 and Schwarz 1979), different species, strains and techniques gave negative results for the genotoxic potential of CCl₄ *in vivo*.

In oral gavage studies, there were no increase in the frequencies of chromosomal aberration, sister chromatid exchange, or micronucleus formation in the liver of rats or in the frequency of micronucleus formation in bone marrow of mice (Sawada et al. 1991; Suzuki et al. 1997).


Covalent adducts of CCl₄ metabolites in the liver had been reported in the literature but the amount of adducts was low as compared to the administered doses. Covalent adducts have no relevant significance if they are the only one sign of genotoxicity.

In conclusion:

The genotoxicity of CCl₄ was evaluated by many international organisations (IARC, 1999; WHO, 1999; ATSDR, 2005; Afsset, 2009; US-EPA, 2010; Anses, 2017). In particular, Anses (2017) applied a *weight of evidence* approach on the results summarized by US EPA (2010)

to conclude on the genotoxic potential of CCl₄. It was concluded that most of the reliable studies (in particular Ames test, *in vivo* micronucleus assays, chromosomal aberrations tests, tests on transgenic animals) gave negative results. Positive results were rather obtained with tests assessing primary DNA damages. The summary of this assessment is provided in table 7.9.5-01.

Table 7.9.5-01. Summary of studies performed with CCl₄ resulting to positive results (red), equivocal results (orange) and negative results (green) depending of the weight of the study (extracted from Anses, 2017).



Based on all these assessments, CCl₄ is not considered as a direct genotoxic agent, unless very high doses are used (*in vitro* only). DNA damages can be due to ROS and/or lipid peroxidation or related to a cytotoxic response since genotoxic effect was only observed at dose high where hepatic cytotoxicity occurred. The role of postulated reactive metabolites (including aldehydes, trichloromethyl or trichloromethylperoxyl free radicals, phosgen) in DNA damage was also hypothesized.

7.9.6. Carcinogenicity

For this endpoint, several studies were available (exposure by oral route and by inhalation). The main target organ (liver) was the same after oral or inhalation exposure.

Human data:

Industry-based studies are available with CCl₄. According to IARC 1999, the risk of cancer has been examined in five occupational populations. In three out of four studies that collected information on non-Hodgkin lymphoma (two cohort investigations and one independent nested case-control study), associations with exposure to CCl₄ were suggested. However, not all of these studies distinguished exposure to CCl₄ specifically, and the associations were not statistically significant.

In the fourth study (another cohort investigation), few men were exposed to CCl₄ and the risk of non-Hodgkin lymphoma was not reported. In addition, no association was found between exposure to CCl₄ and non-Hodgkin lymphoma in a case-control study, although the power to detect an increased risk was low. There was no association between exposure to CCl₄ and lung cancer (nested case-control study) or chronic lymphocytic leukaemia, brain cancer, female breast cancer and intraocular melanoma (population-based case-control studies) (IARC, 1999).

Carcinogenicity, oral:

Only non-reliable carcinogenicity studies by oral exposure were available (in particular due to non adequate duration of exposure). Available data however support the evidence of carcinogenic effects of CCl₄ in the liver of rodents after oral exposure.

In the study of Eschenbrenner (1946), mice were treated with CCl₄ in corn oil by oral gavage with 0, 10, 20, 40, or 80 mg/kg/d daily or 0, 40, 80, or 160 mg/kg bw/d every 4 days for 120 days. Based on the increase of hepatoma incidence, a NOAEL of 10 mg/kg bw/d was identified for the 120-daily exposure. A correlation between the severity of liver necrosis and the incidence of hepatomas in relation to the dose was observed in mice.

In the study of Page et al. (1976), rats and mice were orally treated for 78 weeks. Rats showed severe liver toxicity (fibrosis, bile duct proliferation and regenerative nodule) and a slight increase of the incidence of liver carcinomas and pre-neoplastic lesions for all treatment groups (males: 47 and 94 mg/kg bw/d; females: 80 and 159 mg/kg bw/d). Mice showed severe dose-dependent hepatotoxicity and hepatocellular carcinomas (at 1250 and 1500 mg/kg bw/d). No NOAEL can be derived from this study.

In the study of Weisburger et al. (1977), rats and mice were exposed by gavage to CCl₄ for 78 weeks, with sacrifice at 90 weeks for mice and 110 weeks for rats. Hepatocellular carcinomas and adrenal tumours were observed in mice. In rats, moderate increase of neoplastic nodules and carcinomas of the liver were observed. No NOAEL can be derived from this study.

In contrast, no liver cell carcinoma was reported in hamsters treated once weekly for 30 weeks in corn oil at 19.81 mg/kg bw (Della Porta et al., 1960).

In conclusion, tumorigenic responses had been observed after oral administration of CCl₄. The liver was the main target for tumours' occurrence. The lowest NOAEL identified was 10 mg/kg/d based on hepatomas in mice after exposure to CCl₄ via gavage during 120 days (Eschenbrenner, 1946).

Carcinogenicity, inhalation:

CCl₄ was tested for its carcinogenicity properties after inhalation in the rat and the mouse in a 2-year combined carcinogenicity/repeated dose study of Nagano et al. (2007b). Animals were exposed for 104 weeks, 6 h/d, 5 d/week to concentrations of 5, 25 or 125 ppm (0, 32, 160 and 800 mg/m³). The study was performed in compliance with OECD TG 453 and GLP.

In both species, at 160 and 800 mg/m³ (25 and 125 ppm), a marked to severe liver toxicity and an increase in incidences for liver adenomas (27/50 and 16/50 male mice; 17/50 and 5/49 female mice; 1/50 and 21/50 male rats; 0/50 and 40/50 female rats) and liver carcinomas (44/50 and 47/50 male mice; 33/50 and 48/49 female mice; 0/50 and 32/50 male rats; 3/50 and 15/50 female rats) were observed. The survival rates were decreased for both species at 125 ppm, causally related to various tumors including hepatocellular carcinoma in mice and rats and severe chronic progressive nephropathy in rats. At 32 mg/m³ (5 ppm) the number of liver adenoma or carcinomas in both species were not raised and only minor toxic effects were apparent. In the female mice group at 32 mg/m³ (5 ppm), an increased number of hepatocellular adenomas (8/49 compared to 2/50 in control) was reported but only with a low statistical significance (Fisher exact test, $p < 0.05$). In addition, in mice, the incidence of pheochromocytomas of the adrenal gland (0/50, 0/50, 16/50 and 31/50 males; 0/50, 0/49, 0/50 and 22/49 females) was increased in mid- and high-dose males and in high-dose females.

These data confirmed the liver as primary target for the carcinogenicity of CCl₄. A NOAEL of 5 ppm (= 32 mg/m³) for hepatoadenomas and carcinomas in both species after chronic exposure to CCl₄ via the inhalation route can be derived from this study.

Carcinogenicity, dermal:

No study was available for this endpoint.

General conclusion on carcinogenicity:

Studies in humans are inadequate to show an association between exposure to CCl₄ and carcinogenicity (due to co-exposure for example). None of the human epidemiology studies reported associations to cancer of the liver, which is the main site of carcinogenicity in animal studies. Experimental studies clearly showed that CCl₄ is carcinogenic in animals (in different species and for both sexes).

According to IARC (1999), there is inadequate evidence in humans for the carcinogenicity of CCl₄ but there is sufficient evidence in experimental animals for the carcinogenicity of CCl₄. Overall, IARC evaluation concluded that CCl₄ is possibly carcinogenic to humans (group 2B).

Mecanism of action

The observed tumorigenic response of CCl₄ seems directly linked to its metabolism and secondary to the cytotoxicity of the metabolites. The first step of metabolism by CYP2E1 is an homolytic cleavage of one carbon chlorine bond in CCl₄ to yield chloride ion and the trichloromethyl radical.

In anaerobical conditions, the trichloromethyl radical may undergo several reactions:

- Direct binding to microsomal lipids and proteins
- Addition of a proton and an electron to form chloroform
- Dimerization to form hexachloroethane
- Further reductive dechlorination to form carbon monoxide.

Aerobically, the trichloromethyl radical may be trapped by oxygen to form trichloromethylperoxy radical which decomposes to phosgene (COCl₂), which undergoes hydrolytic cleavage to form CO₂. The trichloromethylperoxy radical is more reactive than the trichloromethyl radical toward amino acid.

Both haloalkylation and lipid peroxidation contribute to loss of cellular functions and subsequent cell death.

Taking into account the results of genotoxicity data, CCl₄ is not considered as a direct genotoxic agent but acts as a carcinogen by a threshold mode of action. Cytotoxicity and regeneration seem therefore to be a main factor in the apparition of (pre-)neoplastic lesions.

In conclusion, CCl₄ is considered to act as a carcinogen by a threshold mode of action. The underlying carcinogenic mode of action is not clearly known. The hypothesis is that CCl₄ is metabolized by CYP2E1 into radicals or other reactive species leading to lipid peroxidation with associated cell cytotoxicity / proliferation (Anses, 2017).

Classification

Appropriate experimental studies clearly shown that CCl₄ is carcinogenic in animals (in different species and for both sexes). In humans, no reliable study allowed to conclude on an association between CCl₄ and cancers.

The substance is currently classified as Carc. Category 2 (Suspected human carcinogen) - H351 according to EU Regulation (EC) No. 1272/2008 (CLP).

eMSCA will consider the opportunity to classify the substance as carcinogenic 1B – H350. Indeed, effects observed in animals may be relevant for humans as reported by Gluchowski NL 2017.

7.9.7. Toxicity to reproduction (effects on fertility and developmental toxicity)

Effects on fertility

There is no reliable study to adequately assess effects of CCl₄ on fertility.

In a study performed by Alumot et al. (1976), the potential of CCl₄ to adversely affect the health and the fertility of rats was analysed in a chronic 2-year feeding study with fumigated food at concentrations of 80 and 200 ppm CCl₄. Females were mated with untreated males, 6 weeks after the start of the treatment, to test their basic reproductive capacity. At intervals of 2 months, 9 males of each dose group were mated with 2 treated females, the other 9 males mating with 18 sterile untreated females. The offspring was examined for litter size, viability, body weight and body weight gain. After study termination the parental animals were analysed for biochemical parameters of liver toxicity.

The treatment groups did not differ in any of the parameter from the control, except for the number of parturitions in the high dose group in the fourth mating. But this rate recovered to normal in the 5th.

However, this study was assigned with a Klimisch score of 4 due to extensive deviations from any available recognised guidelines/protocols for reproductive endpoints (neither OECD guidelines n°416/443 nor RACB (Reproductive Assessment by Continuous Breeding) protocol). The comparison of the protocol study with recognised protocols showed some deviations on the choice of tested doses, exposure design and data collected. Indeed, only two concentrations were tested instead of three as recommended in the protocol and at the highest dose no toxicity was observed. An expected difference in body weight of 10% compared to the controls should be observed, however it was not the case. Although the exposure seems (as the schedule of treatment is unclear) continuous, major differences from the RACB protocol were found, notably the cross mating (task 3 of protocol) and second generation (task 4) were not performed.

The parameters that were evaluated in the Alumot study are not sufficient to assess the capability of the animals to reproduce and to assess potential effects on fertility. In particular, only observations such as % pregnant, % with litters and % of mortality of young (all pregnancies mixed without detailed results) were reported. Several fertility parameters were not analysed such as: day of delivery, sex ratio, development of pups until weaning etc. Furthermore, gross and microscopic observations of all organs and body cavities, reproductive organs weights (ovary, testis, epididymis, seminal vesicle and prostate), oestrous cycle, testicular spermatid head and cauda epididymal sperm counts of the parents and pups should be observed and reported as recommended in the protocol but that is not the case in this study.

Human sperm production appears to be much closer to the infertility threshold; therefore, less severe sperm count reductions may cause human infertility. Indeed, male rats produce a number of spermatozooids that greatly exceed the minimum requirements for fertility, particularly as evaluated in reproductive studies that allow multiple matings. In some strains of rats and mice, sperm production can be drastically reduced (by up to 90% or more) without affecting fertility. It is therefore important to assess the sperm quality of the animals instead of assessing only female fertility index or gestation index. Negative

results in rodent studies that are limited to only fertility and pregnancy outcomes provide insufficient information to conclude that the test substance has no reproductive hazard in humans.

In the absence of a full reproductive toxicity study with CCl₄, other toxicity studies can bring some information on the potential of CCl₄ to affect reproduction. No effect on reproductive organs and tissues were clearly reported in the repeated-dose toxicity studies available. However, it is not clearly specified for these studies if the reproductive organs are analyzed. In this context, it is not possible to conclude if the absence of effect is due to a lack of toxicity or an absence of examination of reproductive organs.

In contrast, testicular atrophy, abnormality in the process of spermatogenesis, inhibition of estrous rhythm and weight and vascularization decreases of ovary and uterus, were reported in the literature (Chatterjee et al., 1966; Chatterjee et al., 1968; Kalla and Bansal 1975). CCl₄ was also used in several studies published in 2013 (Türk G. et al. 2013; Sönmez M. et al. 2013; Yüce A. et al. 2013) as an inductor of sperm damages (including abnormal sperm rate and decreased sperm concentration and motility) and testicular apoptosis in male rats treated weekly with 0.25 ml/kg of CCl₄ in olive oil by gavage for 10 weeks. An oxidative stress mechanism is suspected by formation of free oxygen radicals which have high affinity to cell membrane lipids leading to tissue damage of testis and effects on sperm during maturation. But none of them are carried out or are comparable to current official guidelines.

Developmental toxicity

Several studies are available for this endpoint.

Only one study was available with inhalation exposure (Schwetz, 1974) in which Sprague Dawley rats were exposed to 300 or 1000 ppm CCl₄ for 7h/day on days 6-15 of pregnancy. Evidence of maternal hepatotoxicity was seen in both groups; serum glutamic-pyruvic transaminase (SGPT) was significantly elevated during exposure but had returned to normal by day 21 of gestation when relative liver weights were significantly increased but absolute weights unchanged. There was no statistically significant effect on resorptions though 1/23 litters was fully resorbed in the 1000 ppm group. No gross external abnormalities were seen in any group. The data on internal and skeletal anomalies are difficult to evaluate: only information on the number and percentage of litters affected is given, with no data on the numbers of fetuses affected. However, no significant increases of anomalies are reported, except for subcutaneous oedema in the 300 ppm group and sternebral anomalies in the 1000 ppm group. These increases were judged unlikely to be of any biological significance since oedema was not significantly elevated in the 1000 ppm group and the incidence of sternebral anomalies varied considerably in the two control groups. Foetal body weight and crown-rump length were significantly decreased in a dose related manner but this is not unexpected in view of the severe effect on food consumption in the dams. Therefore, both maternal (hepatotoxicity) and developmental toxicity (body weight and crown-rump length decreased) were observed at a LOAEC of 300 ppm (2.11 g/m³). No NOAEC could be derived.

Four studies by oral route are available.

Rats were treated with 0, 112.5 and 150 mg/kg bw/d of CCl₄ via gavage on gestation days 6-19 (Narotsky et al., 1995). Maternal effects comprised piloerection and weight loss on gestation days 6-8 at both dose groups. An increase of resorption rate at 112.5 and 150 mg/kg bw/d was observed (44.4% and 71.4% compared to 0% in controls).

Litter resorption seems to be the most sensitive developmental toxicity effect of CCl₄ in rats. In this context, Narotsky et al. (1997a) treated pregnant rats with 0, 25, 50 and 75 mg/kg bw/d via gavage on gestation days 6-15. Maternal effects comprised piloerection from 50 mg/kg and weight loss on gestation day (GD) 6-8 at 75 mg/kg bw/d. Embryotoxic effects characterized by full litter resorptions were obvious at 50 mg/kg bw/d and higher. Based on these results, a NOAEL of 25 mg/kg bw/d for developmental toxicity and maternal toxicity in rats was identified.

In order to identify the critical period of CCl₄-induced pregnancy loss in rats, Narotsky *et al.* (1997b) administered the substance (single dose of 150 mg/kg bw) by gavage on gestation day 6, 7, 8, 10 or 12. Full litter resorptions were shown to occur early at GD 6-10 and were absent when rats were treated at GD12. Early in the pregnancy represents a period of susceptibility to acute exposures of CCl₄.

No developmental toxicity was evident in surviving litters.

The following mechanism of action is hypothesized: progesterone could be involved in the full litter resorptions due to maternal hepatic toxicity since liver plays a role in the steroids synthesis and catabolism. This suggests that maternal toxicity could play a role on full litter resorptions. In follow-up investigations, Narotsky *et al.* (1995, 1997)(US EPA, 2010) show association between the response and reduced levels of progesterone and luteinizing hormone. The authors found that after an administration of 150 mg/kg bw CCl₄ on gestation day 8 the level of luteinizing hormone was drastically reduced during a phase of ca. 20 h post administration as compared to controls. Treated rats had significantly more full-litter resorptions (rarely seen in untreated rats of this strain). The effect could be rescued by coadministration of human choriongonadotropin, acting as LH surrogate. This suggests a specific mechanism causing full-litter resorptions.

In a review of the potential teratogenicity of substances emanating from landfill sites (Department of Health, 2001), CCl₄ is suspected not to be embryotoxic by itself, but to cause litter resorptions by disrupting the endocrinal maintenance of pregnancy. The authors concluded "*Reproductive toxicity studies in rats have shown that reproductive effects are only observed at doses causing maternal toxicity. The only embryofetal toxicity reported with inhalation exposure at up to 1000 ppm (6410 mg/m³) CCl₄ during the period of organogenesis was reduced fetal bodyweight and retarded ossification, probably secondary to reduced maternal food intake and bodyweight gain. No fetal malformations were observed. At higher oral doses of 50 mg/kg bodyweight in rats around the time of implantation, complete resorption of litters may be observed which are very probably due to interference with maternal hormonal balance, and not due to a direct embryotoxic effect.*" The effect of subtle hormonal changes potentially induced by lower doses of CCl₄ has not been studied.

Conclusion

There are still some uncertainties related to potential reproductive toxicity due to contradictory data and low relevance of the available studies. However, given the current tonnages and uses of the substance and the risk management measures which should be already in place, considering the known toxicity of the substance, these uncertainties alone do not substantiate a potential risk to be addressed under substance evaluation. This substance evaluation can be concluded without a request for further information.

ECHA has checked the compliance with the standard information requirements under REACH for reproductive toxicity and considered it compliant at the currently registered tonnage levels. However, if the registered tonnage increases in future, the eMSCA recommends ECHA to consider this substance for prioritisation for compliance check.

Classification:

There is no harmonized classification for this endpoint. But 8 notifiers declare a self-classification as Repr. 2 - H361.

Classification for reproductive endpoint could be re-assessed if new information becomes available.

7.9.8. Hazard assessment of physico-chemical properties

Not assessed.

7.9.9. Selection of the critical DNEL(s)/DMEL(s) and/or qualitative/semi-quantitative descriptors for critical health effects

Several toxicological reference values exist in the literature for repeated exposure to CCl₄ by inhalation (ATSDR, 2005; RIVM, 2001; OEHHA, 2000; US EPA, 2010).

For subchronic exposure, a MRL (minimal risk level) of 180 µg/m³ was derived by ATSDR (2005). This value is based on liver effects with a NOAEC of 5 ppm issued from Adams et al. (1952) study.

For chronic exposure, threshold-based toxicological reference values range from 40 µg/m³ (OEHHA, 2000) to 180 µg/m³ (ATSDR, 2005). All these values were based on liver effects.

OEHHA (2000) and US EPA (2010) also derived non-threshold reference values of $4.2 \cdot 10^{-5}$ (µg/m³)⁻¹ and $6 \cdot 10^{-6}$ (µg/m³)⁻¹, respectively, based on the increase of liver tumours.

More recently, Anses (2017) derived a toxicological reference value of 0.11 mg/m³ (0.0184 ppm) for carcinogenicity of CCl₄. This value is based on the increase of liver tumours (threshold mechanism assumed) and intends to protect general population. This value is recommended by eMSCA but is not expected to be used by registrants as no consumer uses are authorized under Regulation (EC) No 1005/2009.

Table 12

| CRITICAL DNELS/DMELS | | | | | |
|------------------------------------|--------------------------------------|---------------------|---|--------------------------------------|--|
| Endpoint of concern | Type of effect | Critical study(ies) | Corrected dose descriptor(s) (e.g. NOAEL, NOAEC) | DNEL/DMEL | Justification/Remarks |
| <i>Carcinogenicity, inhalation</i> | Hepatocellular adenoma and carcinoma | Nagano et al. 2007 | BMDL10%L95% = 2.6 ppm Adjusted BMDL = 2.6 ppm x 6/24 x 5/7 = 0.46 ppm = 2.91 mg/m ³ | 0.11 mg.m ⁻³ (0.0184 ppm) | Uncertainties factors = 25 (interspecies = 2.5 x intraspecies = 10). General population. |

7.9.10. Conclusions of the human health hazard assessment and related classification and labelling

Regarding acute toxicity, CCl₄ is currently classified as Acute Tox 3* for oral, dermal and inhalation routes. The substance is slightly irritant to skin and eye and is a skin sensitizer.

Regarding repeated-dose toxicity by oral and inhalation routes, liver is the most sensitive target organ of the CCl₄ toxicity. The lowest relevant NOAEL after oral administration is 1 mg/kg bw/day from a 12-week study (Bruckner et al., 1986). After inhalation, the lowest NOAEC is 5 ppm from a 2-year study (Nagano et al., 2007b). CCl₄ is currently classified as STOT RE 1.

By a *weight of evidence* approach, CCl₄ is not considered as a direct genotoxic agent but acts as a carcinogen by a threshold mode of action. Indeed, CCl₄ induced liver adenoma and carcinoma after oral and inhalative routes of exposure in rodents. CCl₄ is currently classified as Carc. Cat. 2.

Following the substance evaluation, eMSCA will consider an update of the classification of CCl₄ in order to:

- remove the minimal classification for acute toxicity –Acute tox. 4 – H332;
- add a classification for skin sensitisation properties: Skin Sens. 1B – H317;
- update the classification STOT RE 1 – H372 to add the route of exposure (oral; inhalation) and the target organ (liver);
- update the classification Carc. Cat. 2 – H351 to Carc. Cat. 1B – H350.

7.10. Assessment of endocrine disrupting (ED) properties

7.10.1. Endocrine disruption – Environment

Not specifically assessed.

7.10.2. Endocrine disruption - Human health

Not specifically assessed.

7.10.3. Conclusion on endocrine disrupting properties (combined/separate)

Not specifically assessed.

7.11. PBT and VPVB assessment

Not assessed.

7.12. Exposure assessment

7.12.1. Human health

7.12.1.1. Workers

Considering the high aggregated tonnage, the eMSCA identified, based on the information provided in the chemical safety reports, a potential concern regarding the use of measured data instead of modelling (Tier 1 model TRA Workers 3.0).

In particular, for several contributing scenarios, the lead registrant used the average value of measured data, except in one case where the 90th percentile value is used

(recommended by R14 ECHA Guidance²). It appears that the registrants used the average values instead of the 90th percentile values when RCR were > 1 with exposure concentrations based on 90th percentile values, leading to risks possibly not adequately controlled. This is supported by the estimated concentrations of TRA Workers 3.0 giving RCR >1 with the DNEL proposed by the lead registrant (inhalation route, systemic, long-term). A refined assessment of the following contributing scenarios is therefore recommended:

- Closed manufacturing process (PROC 2);
- Loading of the substance / receiving and charging the substance (PROC 8b);
- Use in laboratory (PROC 15).

Overall, exposure data provided in registration dossier (both modelled and measured) do not exceed OELs recommended by SCOEL.

7.12.1.2. Consumers

The consumer uses are prohibited under Regulation (EC) No 1005/2009 on substances that deplete the ozone layer.

7.12.2. Environment

Exposure assessments provided by 2 registrants have been evaluated.

7.12.2.1. Registrant 1

Exposure scenario 1: Manufacture

CCl₄ is produced on one site. Releases to environmental compartments are based on site specific information and monitoring data, taking into account the following assumptions:

- Water releases are collected and undergo a physico-chemical treatment (distillation with recycling into the process and settling tank) before being sent to an on-site waste water treatment plant.
- Gaseous vents are collected and send to a thermal oxidation treatment
- Wastes generated are collected and send for incineration

Exposure scenario 2: Use at industrial site - Use as solvent

The substance is used as a solvent on one site only, in a closed continuous process. At the use site (delivery by tank truck), CCl₄ is unloaded into a storage tank and is then transferred into a closed reactor where the synthesis takes place. Releases to environmental compartments are based on site specific information and monitoring data, taking into account the following assumptions:

- Water releases are collected and undergo a physico-chemical treatment. The organic phase containing the substance and the aqueous phase are first separated in a settling tank. The organic phase is recycled into the process. A stripping (steam) is carried out on the aqueous phase that is sent to a sewage treatment plant afterwards.
- Gaseous vents are collected and sent to a thermal treatment for incineration. The combustion of these vents produces hydrogen chloride that is then recycled as an aqueous solution. An additional treatment of the vents by adsorption with activated charcoal has recently been implemented in the unit.

² Guidance on Information Requirements and Chemical Safety Assessment. Chapter R.14: Occupational exposure assessment. Version 3.0 - August 2016.

- Wastes generated are collected and sent for incineration

Exposure scenario 3: Use at industrial site - Use as a process agent

The substance is used as a process agent on one site only, in a closed system. Releases to environmental compartments are based on site specific information and monitoring data, taking into account the following assumptions:

- Water releases of substance are minimal as the process operates without water contact and that the CCl₄ resulting from this use is recycled in the process. Moreover, recovery systems are in place in the unit in case of drains/leak.
- Gaseous vents are collected and sent to a thermal treatment for incineration.
- Wastes generated are collected and sent for incineration. The assessment of environmental exposure was carried out by means of EUSES v2.1. Measured data for the environmental releases of CCl₄ were taken into account for the refinement of the release fractions in air and wastewater.

7.12.2.2. Registrant 2

Exposure scenario 1: Manufacture - Manufacture & Dispatch

CCl₄ is produced on one site. Manufactured in closed process and there is no likelihood of exposure. The process is optimized for highly efficient use of raw materials (very minimal environmental release). Volatile compounds subject to air emission controls. Wastewater emissions generated from equipment cleaning are collected in a central container and after neutralization treated by a steam stripper to remove the CCl₄. This waste water is then treated in an onsite WWTP. There are negligible emissions via wastewater and negligible air emissions as the process operates in a contained system.

Risk assessment for manufacturing is based on ESVOC SpERC 1.1.v1. Site specific monitoring data is available and was used to refine the exposure assessment.

Exposure scenario 2: Use at industrial site - Use as intermediate under SCC

For this scenario, all reaction steps and transfers take place under 'strictly controlled conditions' as defined in Chapter 2, Article 18(4) of Regulation (EC) No. 1907/2006. Negligible emissions are assumed for this scenario.

Exposure scenario 3: Use at industrial site - Use as solvent (process agent)

Industrial use of solvent-borne polymer processing materials encompasses a wide range of activities such as material transfers, additives handling, moulding, curing, etc. Substance losses are reduced through use of general and site-specific risk management measures collected on the downstream user sites.

Risk assessment for this use is based on ESVOC SpERC 4.21a.v1 with refinement from site specific data and risk mitigation measures.

Exposure scenario 4: Use by professional worker - Use in laboratories by industrial and professional worker

Exposure assessment for industrial laboratory use is compared to scenario for professional laboratory use as available from the ESVOC SpERC library (ESVOC SpERC 8.17.v1).

7.12.3. Combined exposure assessment

Not assessed.

7.13. Risk characterisation

7.13.1. Environment

Based on site specific information and monitoring data, considering the conditions of use and risk mitigation measures applied for this phase, no environmental risks are identified.

More details are given in the confidential annex.

7.13.2. Human health

Not fully assessed. Regarding occupational exposure, OELs recommended by the SCOEL (2009) could be used by registrants. Exposure data provided in registration dossier (both modelled and measured) do not exceed OELs recommended by SCOEL.

7.14. References

- Adams E. M., Spencer H. C., Rowe V. K., McCollister D. D., Irish D. D. (1952). Vapor toxicity of carbon tetrachloride determined by experiments on laboratory animals. *A M A Arch Ind Hyg Occup Med*, 1952, Vol. 6, No. 1, p. 50-66.
- Alumot E, Nachtom E, Mandel E, Holstein P. (1976). Tolerance and acceptable daily intake of chlorinated fumigants in the rat diet. *Food Cosmet Toxicol.*, vol. 14, no. 2, p. 105-10.
- Anses 2017. Élaboration de VTR chronique par voie respiratoire pour le tétrachlorure de carbone. Avis de l'Anses. Décembre 2017.
- Barbin A., Bereziat J. C. Bartsch H. Evaluation of DNA damage by the alkaline elution technique in liver, kidneys and lungs of rats and hamsters treated with N-nitrosodialkylamines. *Carcinogenesis* 4: 541-545, (1983).
- Bermudez E., Mirsalis J. C., Eales H. C. (1982). Detection of DNA Damage in Primary Cultures of Rat Hepatocytes Following in Vivo and In Vitro Exposure to Genotoxic Agents. *Environmental Mutagenesis* 4:667-679 (1982)..
- Black A. (1982). The Aquatic Toxicity of Organic Compounds to Embryo-Larval Stages of Fish and Amphibians. University of Kentucky Research report No 133. Bogers M, Appelman LM, Feron VJ, Beems RB, Notten WR. (1987). Effects of the exposure profile on the inhalation toxicity of carbon tetrachloride in male rats. *J Appl Toxicol.*, vol. 7, no. 3, p. 185-91.
- BRINGMANN-G/KUHN-R (1980b). Comparison of the toxicity thresholds of water pollutants to bacteria, algae, and protozoa in the cell multiplication inhibition test. *WATER-RES* 14 231-241 1980.
- Bruckner, J., V.; MacKenzie, W., F.; Muralidhara, S.; Luthra, R.; Kyle, G., M.; Acosta, D.; (1986). Oral toxicity of carbon tetrachloride: acute, subacute, and subchronic studies in rats. *Fundamental and applied toxicology*, vol. 6, p. 16-34.
- Bunch RL, Chambers CW (1967). A biodegradability test for organic compounds. *J Water Pollut Control Fed.* 1967 Feb;39(2):181-7.
- Chatterjee A (1966) Testicular degeneration in rats by carbon tetrachloride intoxication. *Experientia(Basel)*, 226: 395-396.
- Chatterjee A (1968). Effect of CCl₄ on gonadal physiology in female rats. *Acta Anat*, 71: 82-86.
- Condie, L., W.; Laurie, R., D.; Mills, T.; Robinson, M.; Bercz, J., P.; (1986). Effect of gavage vehicle on hepatotoxicity of carbon tetrachloride in CD-1 mice: corn oil versus Tween-60 aqueous emulsion. *Fundamental and Applied Toxicology*, vol. 7, p. 199 - 206.
- Della Porta G., Terracini B. and Shubik P. Induction With Carbon Tetrachloride of Liver Cell Carcinomas in Hamster. *Journal of the National Cancer Institute* Vol 26, No 4, 855-863.
- Department of Health (2001), A review of the potential teratogenicity of substances emanating from landfill sites, Sullivan FM, Barlow SM, McElhatton PR, Department of Health/Joint Research Programme on the Possible Health Effects of Landfill Sites.
- EPA (2010). Toxicological review of carbon tetrachloride. EPA/635/R-08/005F.
- Eschenbrenner A. B. and Miller E. (1946). Liver Necrosis and the Induction of Carbon Tetrachloride Hepatomas in Strain A Mice. *J. Nat. Cancer Inst* 6: 325 - 341, (1946). Testing laboratory: NCI, National Institute of Health, US Public Health Service.

Faroon O, Taylor J, Roney N, Fransen ME, Bogaczyk S, Diamond G (2005). Toxicological profile for carbon tetrachloride. U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, Public Health Service, Agency for Toxic Substances and Disease Registry (ATSDR), Division of Toxicology, Atlanta, GA, U. S. A. 358 p.

Foureman P., Mason J. M., Valencia R. and Zimmering S. (1994). Chemical Mutagenesis Testing in *Drosophila*. X. Results of 70 Coded Chemicals Tested for the National Toxicology Program. *Environmental and Molecular Mutagenesis* 23: 208-227 (1994).

de Fouw J (1999). Environmental Health Criteria 208 CARBON TETRACHLORIDE. ISBN 92 4 157208 6, ISSN 0250-863X, self-published WHO, Geneva, Switzerland, 1999 <http://www.inchem.org/documents/ehc/ehc/ehc208.htm>.

Gluchowski NL *et al.* (2017). Lipid droplets and liver disease: from basic biology to clinical implications. *Nat Rev Gastroenterol Hepatol*. 2017 June ; 14(6): 343–355. doi:10.1038/nrgastro.2017.32.

Hayes, J., R.; Condie, L., M., Jr.; Borzelleca, J., F.; (1986). Acute, 14-day repeated dosing, and 90-day subchronic toxicity studies of carbon tetrachloride in CD-1 mice. *Fundam Appl Toxicol.*, vol. 7, no. 3, p. 454-63.

IARC 1999. IARC MONOGRAPHS VOLUME 71. Re-evaluation of Some Organic Chemicals, Hydrazine and Hydrogen Peroxide. <https://monographs.iarc.fr/iarc-monographs-on-the-evaluation-of-carcinogenic-risks-to-humans-50/>.

Kalla NR & Bansal MP (1975). Effect of carbon tetrachloride on gonadal physiology in male rats. *Acta Anat*, 91: 380-385.

KAZANTZIS G, BOMFORD RR. Dyspepsia due to inhalation of carbon tetrachloride vapour. *Lancet*. 1960 Feb 13;1(7120):360-2.

Koporec, K., P.; Kim, H., J.; MacKenzie, W., F.; Bruckner, J., V.; (1995). Effect of oral dosing vehicles on the subchronic hepatotoxicity of carbon tetrachloride in the rat. *J Toxicol Environ Health*, vol. 44, no. 1, p. 13-27.

Kutepov, E., N.; (1968). Experimental data for the establishment of standards for carbon tetrachloride in bodies of water. *Gig Samit*, vol. 33, p. 35-41.

MacEwen JD, Geckler RP. (1966). Comparative toxicity studies on animals exposed continuously for periods up to 90 days to NO₂, O₃, and CCl₄ in ambient air vs. 5 psia 100 per cent oxygen atmosphere. AMRL-TR-66-120. AMRL TR. 1966 Dec:238-59.

Mirsalis J. C., Tyson K. C., Butterworth B. E. Detection of Genotoxic Carcinogens in the In Vivo-In Vitro Hepatocyte DNA Repair Assay. *Environmental Mutagenesis* 4: 553 - 562 (1982).

Nagano K, Umeda, Saito, Nishizawa, Ikawa, Arito H, Yamamoto S, Fukushima S; (2007a). Thirteen-week inhalation toxicity of carbon tetrachloride in rats and mice. *J Occup Health* 2007; 49: 249-259.

Nagano K, Sasaki T, Umeda Y, Nishizawa T, Ikawa N, Ohbayashi H, Arito H, Yamamoto S, Fukushima S; (2007b). Inhalation Carcinogenicity and Chronic Toxicity of Carbon Tetrachloride in Rats and Mice. *Inhalation Toxicology*, vol. 19, no. 13, p. 1089-1103.

Narotsky MG, Kavlock RJ. (1995). A multidisciplinary approach to toxicological screening: II. Developmental toxicity. *J Toxicol Environ Health*, no. 45, vol. 2, p. 145-71.

Narotsky MG, Brownie CF, Kavlock RJ. (1997a). Critical period of carbon tetrachloride-induced pregnancy loss in Fischer-344 rats, with insights into the detection of resorption sites by ammonium sulfide staining. *Teratology*, vol. 56, no. 4, p. 252-61.

Narotsky MG, Pegram RA, Kavlock RJ. (1997b). Effect of dosing vehicle on the developmental toxicity of bromodichloromethane and carbon tetrachloride in rats. *Fundam Appl Toxicol.*, vol. 40, no 1, p. 30-36.

Norwood, W.D., P.A. Fuqua, and B.C. Scudder. 1950. Carbon tetrachloride poisoning: More regulation, more education needed. *Arch. Ind. Hyg. Occup. Med.* 1(1):90-100.

Sasaki Y. F., Safa A., Akasaka M., Ishibashi S., Yoshida K., Su Y. Q., Matsusaka N. and Tsuda S. (1998). Detection of in vivo genotoxicity of haloalkanes and haloalkenes carcinogenic to rodents by the alkaline single cell gel electrophoresis (comet) assay in multiple mouse organs. *Mutation Research* 419, 13 - 20 (1998).

Sawada S., Yamanaka T., Yamatsu K., Furihata C. and Matsushima T. (1991). Chromosome aberrations, micronuclei and sister-chromatid exchanges (SCEs) in rat liver induced in vivo by hepatocarcinogens including heterocyclic amines. *Mutation Research*, 251, 59-69 (1991).

Schwarz M., Hummel J., Appel K. E., Rickart R. and Kunz W. (1979). DNA Damage induced in vivo evaluated with a non-radioactive alkaline elution technique. *Cancer Letters*, 6, 221-226, (1979).

Schwetz B. A., Leong B. K. J., Gehring P. J. (1974). Embryo- and Fetotoxicity of Inhaled Carbon Tetrachloride, 1,1-Dichloroethane and Methyl Ethyl Ketone in Rats. *Toxicology and Applied Pharmacology*, vol. 28, p. 452-464.

Smyth SF, Carpenter CP, (1936). The chronic toxicity of carbon tetrachloride; Animal exposures and field studies. *The Journal of industrial hygiene and toxicology*. vol. 18, no. 5, p. 277- 298.

Sönmez M. et al. (2013). Quercetin attenuates carbon tetrachloride-induced testicular damage in rats. *Andrologia*. 2014 Oct;46(8):848-58.

Stewart B. W. Generation and Persistence of Carcinogen-induced Repair Intermediates in Rat Liver DNA in vivo. *Cancer Research* 41: 3238 - 3243.

Suzuki H., Hirano N., Watanabe C. and Tarumoto Y. (1997). Carbon tetrachloride does not induce micronucleus in either mouse bone marrow or peripheral blood. *Mutation Research* 394, 77-80 (1997).

Tabak HH, Quave SA, Mashni CI, Barth EF (1981). Biodegradability studies with organic priority pollutant compounds. *J Water Pollut Control Fed.* 53(10): 1503-17.

Tomenson JA, Baron CE, O'Sullivan JJ, Edwards JC, Stonard MD, Walker RJ, Fearnley DM. (1995). Hepatic function in workers occupationally exposed to carbon tetrachloride. *Occup Environ Med*, vol. 52, no. 8, p. 508-14.

Türk G *et al.* (2013). Ameliorating effect of pomegranate juice consumption on carbon tetrachloride-induced sperm damages, lipid peroxidation, and testicular apoptosis. *Toxicol Ind Health*. 2016 Jan;32(1):126-37

Weisburger E. K. (1977). Carcinogenicity Studies on Halogenated Hydrocarbons. *Environmental Health Perspectives* 21: 7-16, 1977.

Yüce A *et al.* (2013). Effectiveness of cinnamon (*Cinnamomum zeylanicum*) bark oil in the prevention of carbon tetrachloride-induced damages on the male reproductive system. *Andrologia*. 2014 Apr;46(3):263-72.

7.15. Abbreviations

CCH / DEV: complicity check / dossier evaluation

CCl₄: carbon tetrachloride

EOGRTS: Extended One Generation Reproduction Toxicity Study

PNDT: Prenatal developmental toxicity

Confidential annex is removed from the public version.